Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             676 results found
no title author magazine year volume issue page(s) type
1 Author index 2006
 36 S2 p. S221-S235
15 p.
 article
2 Conflict of interest disclosure 2006
 36 S2 p. S219-9S20
nvt p.
 article
3 Foreword 2006
 36 S2 p. iii-
1 p.
 article
4 O.092 A mathematical model of dynamics for anti-HBV infection treatment with peginterferon alpha-2a Min, L.
 2006
 36 S2 p. S27-
1 p.
 article
5 O.081 An adaptor protein AP-50 peptide inhibits serum-derived hepatitis C virus infection in normal human hepatocytes Buck, M.M.
 2006
 36 S2 p. S25-
1 p.
 article
6 O.029 Analysis of hepatitis E virus mutants in a new cell culture system Emerson, S.U.
 2006
 36 S2 p. S9-
1 p.
 article
7 O.159 A new class of biomarkers for hepatocellular carcinoma: IgM immune complexes Beneduce, L.
 2006
 36 S2 p. S48-S49
2 p.
 article
8 O.101 A novel primboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIa clinical trial Schneider, J.
 2006
 36 S2 p. S30-
1 p.
 article
9 O.114 An overview of genetic diversity and its impact on diagnostic assays Hollinger, F.B.
 2006
 36 S2 p. S34-
1 p.
 article
10 O.065 Anti golgi complex antibodies during pegylated interferon therapy for hepatitis C: What does it mean? Paraná, R.
 2006
 36 S2 p. S20-
1 p.
 article
11 O.072 Antiviral-resistant HBV: Can we prevent this monster from growing? Lok, A.S.F.
 2006
 36 S2 p. S22-
1 p.
 article
12 O.095 Antiviral therapy for HCV-associated cryoglobulinemia vasculitis: A long term follow-up Cacoub, P.
 2006
 36 S2 p. S27-S28
2 p.
 article
13 O.064 Antiviral treatment for hepatitis C virus infection in the real practice: A nationwide Italian experience (the PROBE study) Alberti, A.
 2006
 36 S2 p. S20-
1 p.
 article
14 O.015 A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002) Frey, S.E.
 2006
 36 S2 p. S5-
1 p.
 article
15 O.156 A phenylalanine mutation in the precore region of both hepatitis B virus and woodchuck hepatitis virus induces endoplasmic reticulum stress Kew, M.C.
 2006
 36 S2 p. S48-
1 p.
 article
16 O.120 A reappraisal of the genetic diversity of hepatitis B virus American genotypes Pujol, F.H.
 2006
 36 S2 p. S36-
1 p.
 article
17 O.162 A study to assess treatment with peginterferon alpha-2b and ribavirin in naive patienst with genotype 1 chronic hepatitis C and slow virological response (SUCCESS study) E, R.
 2006
 36 S2 p. S50-
1 p.
 article
18 O.167 Basal core promoter mutations and primary liver cancer Fang, Z.-L.
 2006
 36 S2 p. S51-
1 p.
 article
19 O.107bis Development of therapeutic vaccines for hepatitis B and C Depla, E.
 2006
 36 S2 p. S32-
1 p.
 article
20 O.160bis New HCV antiviral therapies Zeuhem, S.
 2006
 36 S2 p. S49-S50
2 p.
 article
21 O.027 Broad reactivity of two anti-E2 human monoclonal antibodies against HCV quasispecies after liver transplantation Nussbaum, O.
 2006
 36 S2 p. S8-
1 p.
 article
22 O.175 Cell culture-, serum- and liver-derived hepatitis C virus particles: biophysical properties, infectivity and neutralization Petit, M.-A.
 2006
 36 S2 p. S54-
1 p.
 article
23 O.145 Changes in medical resource utilisation by subjects who are tested HCV seropositive during routine medical check-up (1994–2003) Gaudy, C.
 2006
 36 S2 p. S45-
1 p.
 article
24 O.098 Changes in NK cell repertoire after therapeutic HBV vaccination could be correlated to induction of HBV-specific T-cell responses Scott-Algara, D.
 2006
 36 S2 p. S28-S29
2 p.
 article
25 O.170 Characterization and functional analyses of hepatitis B virus (HBV) isolated from liver tissue of patients with occult HBV infection Pollicino, T.
 2006
 36 S2 p. S52-
1 p.
 article
26 O.006 Characterization of RNA-directed transcription of human hepatitis delta virus RNA Taylor, J.M.
 2006
 36 S2 p. S2-
1 p.
 article
27 O.045 Chronic hepatitis B: When to institute treatment Heathcote, J.
 2006
 36 S2 p. S14-
1 p.
 article
28 O.040 Classification of hepatitis B virus genotypes into higher-order genetic groups Purdy, M.A.
 2006
 36 S2 p. S12-S13
2 p.
 article
29 O.104 Codelivery of cytokine genes with DNA vaccine to duck hepatitis B virus proteins improves its therapeutic efficacy Saade, F.
 2006
 36 S2 p. S31-
1 p.
 article
30 O.118 Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection Ansaldi, F.
 2006
 36 S2 p. S35-S36
2 p.
 article
31 O.103 Combination therapy with antiviral drugs and immunomodulation against chronic hepatitis B virus infection: Evaluation in the woodchuk model Lu, M.
 2006
 36 S2 p. S30-S31
2 p.
 article
32 O.102 Combination therapy with entecavir and “prime-boost” vaccines prevents the development of chronic duck hepatitis B virus infection Miller, D.S.
 2006
 36 S2 p. S30-
1 p.
 article
33 O.158 Correlation of HBV genotypes and mutants with long-term outcomes of patients who underwent resection of hepatocellular carcinoma Wu, J.C.
 2006
 36 S2 p. S48-
1 p.
 article
34 O.012 Cross-reactive epitopes identified in hepatitis C virus envelope proteins induce antibodies that capture virions from infected patients' sera and neutralize HCV/HIV pseudotypes Grollo, L.
 2006
 36 S2 p. S4-
1 p.
 article
35 O.008 Cytoplasm-localized large hepatitis delta antigen interferes clathrin-mediated protein trafficking Huang, C.
 2006
 36 S2 p. S2-S3
2 p.
 article
36 O.096 Deregulation of squamous cell carcinoma antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C Vidalino, L.
 2006
 36 S2 p. S28-
1 p.
 article
37 O.052 Detection of intrahepatic virus-specific T-cells in marmosets with resolved GBV-B infection Woollard, D.J.
 2006
 36 S2 p. S16-
1 p.
 article
38 O.021 Determinants of infectivity in the antigenic loop of hepatitis B virus envelope proteins Abou Jaoudé, G.
 2006
 36 S2 p. S6-S7
2 p.
 article
39 O.076 Development of RNA interference-based strategies to control hepatitis B virus clinical isolate of various genotypes and mutants and prevent emergence of resistant mutants Wu, H.L.
 2006
 36 S2 p. S23-
1 p.
 article
40 O.187 Differential responsiveness of CD4 and CD8 T-cells during acute HCV re-infection Longworth, S.
 2006
 36 S2 p. S56-S57
2 p.
 article
41 O.185 Drug-drug interaction between clevudine in combination with telbivudine or 3TC in human liver cells Hernandez-Santiago, B.I.
 2006
 36 S2 p. S56-
1 p.
 article
42 O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus McHutchison, J.G.
 2006
 36 S2 p. S31-
1 p.
 article
43 O.091 Early prediction of response to Peg-IFNα-2a or Peg-IFNα-2b plus ribavirin in the single chronic hepatitis C patients by modeling the dynamics of infected cells Ciccorossi, P.
 2006
 36 S2 p. S26-S27
2 p.
 article
44 O.087 E6-associated protein mediates ubiquitylation and degradation of hepatitis C virus core protein Shoji, I.
 2006
 36 S2 p. S26-
1 p.
 article
45 O.063 Effectiveness and tolerability of pegIntron® in combination with Rebetol® in real life: The pegIntrust study Adler, M.
 2006
 36 S2 p. S19-
1 p.
 article
46 O.004 Elements of pathogenesis and natural history of HEV infection Krawczynski, K.
 2006
 36 S2 p. S1-
1 p.
 article
47 O.034 Emerging infections that threaten the blood supply Alter, H.J.
 2006
 36 S2 p. S11-
1 p.
 article
48 O.031 Enhanced alpha-1 microglobulin secretion from hepatitis E virus ORF3 expressing human hepatoma cells is mediated by the tumor susceptibility gene 101 Lal, S.K.
 2006
 36 S2 p. S10-
1 p.
 article
49 O.066 Enhanced spontaneous apoptosis of peripheral blood leucocytes from HCV-infected patients is not modulated by current therapy with pegylated interferon alpha and ribavirin Davila, L.
 2006
 36 S2 p. S20-
1 p.
 article
50 O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) Yurdaydin, C.
 2006
 36 S2 p. S55-
1 p.
 article
51 O.164 Eradication of HCV and regression of fibrosis, in chronic hepatitis C patients with sustained virological response to therapy Maylin, S.M.
 2006
 36 S2 p. S50-S51
2 p.
 article
52 O.075 Evaluation of replication capacity and cross-resistance of HBV drug resistant mutants Villet, S.
 2006
 36 S2 p. S23-
1 p.
 article
53 O.019 Expansion of HBV S gene heterogeneity in chimpanzees after experimental inoculation with HBV sT126N mutant Araujo, A.
 2006
 36 S2 p. S6-
1 p.
 article
54 O.121 Expression of hepatitis B virus surface antigens (HBsAg) in mammalian cells: Characterization of a genotype F variant deficient in HBsAg secretion Araujo, N.M.
 2006
 36 S2 p. S36-S37
2 p.
 article
55 O.049 Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma Lampertico, P.
 2006
 36 S2 p. S15-S16
2 p.
 article
56 O.025 Full-length preS1-preS2-HBs antigen (HBsAg) sequence analysis of HBV surface mutants in HBV DNA-positive organ, tissue and cell donors with various HBV serological profiles Chevaliez, S.
 2006
 36 S2 p. S8-
1 p.
 article
57 O.132 Functional interaction between HBX and the histone acetyltransferase CBP/p300 Cougot, D.
 2006
 36 S2 p. S40-
1 p.
 article
58 O.122 Genetic analysis of North-African hepatocellular carcinoma delineates specific alteration profiles Pineau, P.
 2006
 36 S2 p. S37-
1 p.
 article
59 O.117 Genetic diversity and complexity changes correlate with early virological response during chronic hepatitis C therapy Kaczanowski, R.
 2006
 36 S2 p. S35-
1 p.
 article
60 O.099 HBsAg-HBIg complex modulates antigen presentation of dendritic cells from chronic hepatitis B patients Zheng, B.
 2006
 36 S2 p. S29-
1 p.
 article
61 O.115 HBsAg polymorphisms: Implications for assay design Roque-Afonso, A.
 2006
 36 S2 p. S34-S35
2 p.
 article
62 O.020 HBV/HCV: Animal/cellular models Petersen, J.
 2006
 36 S2 p. S6-
1 p.
 article
63 O.136 HBV translocates across placental trophoblasts Bhat, P.
 2006
 36 S2 p. S42-
1 p.
 article
64 O.097 HCV infection, cryoglobulinemia and lymphomagenesis: An emerging picture Dammacco, F.
 2006
 36 S2 p. S28-
1 p.
 article
65 O.171 HDL inhibits HCV neutralisation by CD81-NOB antibodies by stimulating cell entry through activation of the scavenger receptor BI Dreux, M.
 2006
 36 S2 p. S52-S53
2 p.
 article
66 O.137 HDL inhibits neutralisation by HCV antibodies via a ternary interaction with the scavenger receptor BI Dreux, M.
 2006
 36 S2 p. S42-
1 p.
 article
67 O.009 HDV-WHV genotypes and outcome of superinfection in woodchuck model D'Ugo, E.
 2006
 36 S2 p. S3-
1 p.
 article
68 O.001 Hepatis A: molecular virology and pathogenesis Martin, A.
 2006
 36 S2 p. S1-
1 p.
 article
69 O.044 Hepatitis B epidemiology and prevention: where are we in Europe in 2006 Van Damme, P.
 2006
 36 S2 p. S14-
1 p.
 article
70 O.022 Hepatitis B virus infection is dependent on a multistep attachment and entry process mediated by the preS1 and the S-domain Glebe, D.
 2006
 36 S2 p. S7-
1 p.
 article
71 O.035 Hepatitis B virus infection 25 years after the development of an effective vaccine Mele, A.
 2006
 36 S2 p. S11-
1 p.
 article
72 O.131 Hepatitis B virus X protein causes mutation of cellular gene by ROS generation Koike, K.
 2006
 36 S2 p. S40-
1 p.
 article
73 O.141 Hepatitis C virus transmission from healthcare workers to patients in the USA Williams, I.T.
 2006
 36 S2 p. S43-S44
2 p.
 article
74 O.067 Hepatitis C virus: Virology, immunology, natural history, treatment Bartenschlager, R.
 2006
 36 S2 p. S21-
1 p.
 article
75 O.003 Hepatitis E: light at the end of the tunnel? Purcell, R.H.
 2006
 36 S2 p. S1-
1 p.
 article
76 O.030 Hepatitis E virus ORF2 and ORF3 proteins are encoded by a bicistronic subgenomic mRNA Graff, J.
 2006
 36 S2 p. S9-S10
2 p.
 article
77 O.150 Hepatocyte turnover in the resolution of transient and progression of chronic hepadnavirus infections Mason, W.S.
 2006
 36 S2 p. S46-
1 p.
 article
78 O.157 High dose 3D conformal radiation therapy in cirrhotic patients with small hepatocellular carcinomas Merle, P.
 2006
 36 S2 p. S48-
1 p.
 article
79 O.161 High SVR rates with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 patients with a week-4 virological response Ferenci, P.
 2006
 36 S2 p. S50-
1 p.
 article
80 O.014 Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects Michel, M.L.
 2006
 36 S2 p. S4-
1 p.
 article
81 O.056 Immune response and viral tolerance during chronic HBV infection Bertoletti, A.
 2006
 36 S2 p. S17-
1 p.
 article
82 O.149 Immunopathogenesis of HBV infection Ferrari, C.
 2006
 36 S2 p. S46-
1 p.
 article
83 O.058 Impact of human hepatocyte MHC-class I antigen presentation on virus-specific CD8 T cell function Gehring, A.J.
 2006
 36 S2 p. S17-S18
2 p.
 article
84 O.142 Incidence and risk factors for hepatitis C in the USA, 1982–2004: The role of injection drug use Williams, I.T.
 2006
 36 S2 p. S44-
1 p.
 article
85 O.043 Incidence of acute hepatitis B in the USA, 1990–2005 Finelli, L.
 2006
 36 S2 p. S13-S14
2 p.
 article
86 O.086 Inhibition of hepatitis C virus replication by PKR Chang, J.
 2006
 36 S2 p. S26-
1 p.
 article
87 O.190 Inhibition of hepatitis C virus replication by tumor suppressor p53: Novel prospects of p53 in antiviral defense Dharel, N.
 2006
 36 S2 p. S57-S58
2 p.
 article
88 O.069 Innate and adaptive immune responses to HCV Rehermann, B.
 2006
 36 S2 p. S21-S22
2 p.
 article
89 O.194 Interaction of HCV proteins with host cell membranes and lipids Penin, F.
 2006
 36 S2 p. S58-S59
2 p.
 article
90 O.189 Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection Maouzi, A.B.
 2006
 36 S2 p. S57-
1 p.
 article
91 O.196 Interferon response against HCV Seeger, C.
 2006
 36 S2 p. S59-
1 p.
 article
92 O.193 Internal ribosomal entry site (IRES)-dependent tropism of hepatitis C virus Di Liberto, G.
 2006
 36 S2 p. S58-
1 p.
 article
93 O.146 Intrafamilial and household clustering of hepatitis C virus in rural Egypt: A phylogenetic and matrix correlation tests analysis Feray, C.
 2006
 36 S2 p. S45-
1 p.
 article
94 O.144 Intra-familial transmission of HCV infection in a rural area from Egypt Plancoulaine, S.
 2006
 36 S2 p. S44-S45
2 p.
 article
95 O.184 In vivo inhibition of HBV infection by acylated preS peptides in the urokinase-type plasminogen activator (UPA) mouse model Petersen, J.
 2006
 36 S2 p. S55-S56
2 p.
 article
96 O.061 Lamivudine treatment for acute hepatitis B — a randomized controlled trial Sarin, S.K.
 2006
 36 S2 p. S18-S19
2 p.
 article
97 O.130 Liver neoplasia induced by a cancer-associated hepatitis B virus mutant Huang, Z.
 2006
 36 S2 p. S39-S40
2 p.
 article
98 O.180 Longer survival of liver transplant recipients with hepatitis virus coinfections Rifai, K.
 2006
 36 S2 p. S55-
1 p.
 article
99 O.128 Long-term maintenance ribavirin monotherapy in chronic hepatitis C patients not responding or intolerant to interferon alpha Trépo, C.
 2006
 36 S2 p. S39-
1 p.
 article
100 O.074 Management of HBV drug resistance in patients with severe cirrhosis and post-liver transplantation Villenueve, J.-P.
 2006
 36 S2 p. S23-
1 p.
 article
101 O.125 Management of treatment non-responders in chronic hepatitis C Poynard, T.
 2006
 36 S2 p. S38-
1 p.
 article
102 O.133 Mechanism of HBV-associated hepatocarcinogenesis by modulation of MAPK pathways and cell cycle regulation Chin, R.
 2006
 36 S2 p. S41-
1 p.
 article
103 O.134 Mechanism of p53 activation by hepatitis B virus X protein leading to hepatocyte apoptosis Wang, W.
 2006
 36 S2 p. S41-
1 p.
 article
104 O.138 Modulation of endoplasmic reticulum (ER) calcium signalling affects hepatitis C virus (HCV) protein expression and replication Paterlini-Bréchot, P.
 2006
 36 S2 p. S42-S43
2 p.
 article
105 O.041 Molecular signature motifs of HBV subgenotypes: An analysis based on all open reading frames Norder, H.
 2006
 36 S2 p. S13-
1 p.
 article
106 O.039 Molecular tools in epidemiological investigations Magnius, L.O.
 2006
 36 S2 p. S12-
1 p.
 article
107 O.143 Monitoring of end-stage liver disease associated with hepatitis C virus (HCV) infection in Scotland: Record-linkage study Hutchinson, S.J.
 2006
 36 S2 p. S44-
1 p.
 article
108 O.165 Naturally occurring mutations that regulate hepatitis B e antigen expression Tong, S.
 2006
 36 S2 p. S51-
1 p.
 article
109 O.079 Novel sustained release formulation of IFN α-2b improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial Trépo, C.
 2006
 36 S2 p. S24-
1 p.
 article
110 O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE) Zeuzem, S.
 2006
 36 S2 p. S49-
1 p.
 article
111 O.033 Outbreaks of hepatitis A in western India: 2002–2004 Chadha, M.S.
 2006
 36 S2 p. S10-
1 p.
 article
112 O.135 Over-expression of oncogenic microRNA polycistron miR-17-92 in primary woodchuck hepatocellular carcinomas Melegari, M.
 2006
 36 S2 p. S41-
1 p.
 article
113 O.085 Overexpression of the Wnt/Frizzled signal's memebers: A strikingly common and early event in human hepatocellular carcinoma (HCC) Bengochéa, A.
 2006
 36 S2 p. S25-S26
2 p.
 article
114 O.123 Pattern of HBV/HCV infection and TP53/beta-catenin mutations in HCC cases from Thailand Galy, O.
 2006
 36 S2 p. S37-
1 p.
 article
115 O.010 Peculiar fulminant HDV hepatitis in Amazonia Paraná, R.
 2006
 36 S2 p. S3-
1 p.
 article
116 O.106 Pharmakokinetics, safety, tolerability, and pharmacodynamics of the isatoribine oral prodrug ANA975 in a multidose phase 1 healthy volunteer study Kerr, B.
 2006
 36 S2 p. S31-S32
2 p.
 article
117 O.127 Phase 2b interim (week 12) results of albumin interferon alpha-2b combined with ribavirin in IFN-naïve, genotype 1 chronic hepatitis C infection Benhamou, Y.
 2006
 36 S2 p. S38-S39
2 p.
 article
118 O.013 Potent T-cell immunity induced by a hepatitis C virus candidate vaccine based on a non-replicative poxvirus Inchauspe, G.J.
 2006
 36 S2 p. S4-
1 p.
 article
119 O.037 Prediction of HCV-related morbidity and mortality burden in France using the back-calculation method Deuffic-Burban, S.
 2006
 36 S2 p. S11-S12
2 p.
 article
120 O.017 Primary and secondary occult hepadnaviral infections: identification and differential characteristics Michalak, T.I.
 2006
 36 S2 p. S5-S6
2 p.
 article
121 O.195 Production of infectious HCV particles in three-dimensional liver cultures Miyamura, T.
 2006
 36 S2 p. S59-
1 p.
 article
122 O.191 Production of infectious hepatitis C virus in cultured cells Wakita, T.
 2006
 36 S2 p. S58-
1 p.
 article
123 O.172 Production of infectious hepatitis C virus of various genotypes in cell culture Kato, T.
 2006
 36 S2 p. S53-
1 p.
 article
124 O.177 Prophylactic therapy and treatment of HBV reinfection in liver transplant recipients Terrault, N.A.
 2006
 36 S2 p. S54-S55
2 p.
 article
125 O.005 Protection against hepatitis E by a recombinant vaccine Shrestha, M.P.
 2006
 36 S2 p. S2-
1 p.
 article
126 O.107 Protective CD8+ T cell responses in hepatitis C virus infected/exposed individuals Bharadwaj, M.
 2006
 36 S2 p. S32-
1 p.
 article
127 O.116 Reasons for the lack of anti-HBC antibody detection in hepatitis B virus chronically infected patients Avettand-Fenoel, V.
 2006
 36 S2 p. S35-
1 p.
 article
128 O.024 Recent insights into HCV natural history and pathogenesis from studies of infected blood donors and recipients Busch, M.P.
 2006
 36 S2 p. S7-S8
2 p.
 article
129 O.100 Relationship between T cell responses and suppression of viral rebound in chronic hepatitis B carriers received combination therapy with DNA vaccine and chemical drug Yang, S.
 2006
 36 S2 p. S29-
1 p.
 article
130 O.169 Replication efficiency of hepatitis B virus infectious clones bearing core promoter, pre-core and surface gene mutations, in a common genetic background Jammeh, S.
 2006
 36 S2 p. S52-
1 p.
 article
131 O.051 Replication of infectious wild-type HCV in cultured human T cells MacParland, S.A.
 2006
 36 S2 p. S16-
1 p.
 article
132 O.112 Replicative regulating function detected in the “turn” of the “helix clamp” of hepatitis B virus reverse transcriptase Wang, Y.X.
 2006
 36 S2 p. S33-S34
2 p.
 article
133 O.124 Risk of cirrhosis with exposure to aflatoxin and hepatitis B and C viruses Kirk, G.D.
 2006
 36 S2 p. S37-S38
2 p.
 article
134 O.068 Robust hepatitis C virus infection in vitro: coevolution of virus and host Chisari, F.V.
 2006
 36 S2 p. S21-
1 p.
 article
135 O.110 Role of cellular differentiation for the efficiency of HBV replication Quasdorff, M.
 2006
 36 S2 p. S33-
1 p.
 article
136 O.084 Role of frizzled-7 receptor overexpression in HBV and HCV related human hepatocellular carcinoma Wands, J.R.
 2006
 36 S2 p. S25-
1 p.
 article
137 O.168 Rolling circle amplification technology for the study of HBV variants Margeridon, S.
 2006
 36 S2 p. S51-S52
2 p.
 article
138 O.192 Scavenger receptor class B type I is a co-receptor for infection with cell culture-derived hepatitis C virus Zeisel, M.B.
 2006
 36 S2 p. S58-
1 p.
 article
139 O.129 Screening and primary to tertiary prevention of HCC Omata, M.
 2006
 36 S2 p. S39-
1 p.
 article
140 O.032 Sequential saliva testing used in the investigation of a hepatitis A outbreak, Auvergne (France), December 2004 Santa-Olalla, P.
 2006
 36 S2 p. S10-
1 p.
 article
141 O.211 Severe acute hepatitis during Chikungunya virus infection on Reunion Island: case report from 14 observations Garnier, P.
 2006
 36 S2 p. S60-
1 p.
 article
142 O.207 Shall we treat acute hepatitis B virus infection? Tillmann, H.L.
 2006
 36 S2 p. S59-
1 p.
 article
143 O.094 Splenic lymphoma with villous lymphocytes associated with type II cryoglobulinemia and HCV infection: A new entity? Saadoun, D.
 2006
 36 S2 p. S27-
1 p.
 article
144 O.174 Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus Rouillé, Y.
 2006
 36 S2 p. S53-S54
2 p.
 article
145 O.155 Surveillance of patients at risk Colombo, M.
 2006
 36 S2 p. S47-
1 p.
 article
146 O.042 The added value of molecular analysis in the source and contact tracing of hepatitis B transmission in a community Mostert, M.
 2006
 36 S2 p. S13-
1 p.
 article
147 O.140 The HCV E2 protein is a kinase, with homology to auxilin 2, involved in clathrin mediated endocytosis Buck, M.
 2006
 36 S2 p. S43-
1 p.
 article
148 O.007 The HDV/HepaRG model for in vitro analysis of the HBV envelope protein functions at viral entry Sureau, C.
 2006
 36 S2 p. S2-
1 p.
 article
149 O.109 The hepatitis B virus HBx protein stimulates viral replication and induces mitotic defects by binding to host cell protein DDB1 Leupin, O.
 2006
 36 S2 p. S32-S33
2 p.
 article
150 O.028 The HEV ORF3 protein downregulates the mitochondrial death pathway through increased expression and oligomerization of VDAC Moin, S.M.
 2006
 36 S2 p. S9-
1 p.
 article
151 O.055 The human liver-uPA-SCID mouse: a chimeric rodent model for the study of viral hepatitis Meuleman, P.
 2006
 36 S2 p. S17-
1 p.
 article
152 O.053 The human liver uPA-SCID mouse, a preclinical model to test anti-hepatitis C compounds Vanwolleghem, T.
 2006
 36 S2 p. S16-S17
2 p.
 article
153 O.038 The importance of surveillance for the management of viral hepatitis Lavanchy, D.
 2006
 36 S2 p. S12-
1 p.
 article
154 O.148 The natural history of chronic hepatitis B Lai, C.-L.
 2006
 36 S2 p. S45-
1 p.
 article
155 O.060 The outcome of combined antiviral therapy in tolerant children with chronic hepatitis B is associated with emergence of mutations within HBV core gene immunodominant epitopes Carey, I.
 2006
 36 S2 p. S18-
1 p.
 article
156 O.188 The primary transcriptional response to interferon-α-2a and -alpha-2b in patients with chronic hepatitis C correlates with the immediate and sustained antiviral response Trippler, M.
 2006
 36 S2 p. S57-
1 p.
 article
157 O.018 Therapeutic vaccination in chronic hepatitis B: pre-clinical studies in the woodchuck Roggendorf, M.
 2006
 36 S2 p. S6-
1 p.
 article
158 O.151 Therapy of hepatitis B. Overview Hoofnagle, J.H.
 2006
 36 S2 p. S46-S47
2 p.
 article
159 O.062 The safety and efficacy of Viramidine® plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV: Phase 3 results Murphy, B.
 2006
 36 S2 p. S19-
1 p.
 article
160 O.080 The unique inhibition mechanism of intrabodies against hepatitis C virus serine protease and their additive effect with IFN-alpha Gal-Tanamy, M.
 2006
 36 S2 p. S24-S25
2 p.
 article
161 O.016 Towards effective prophylactic and therapeutic vaccination against HCV Folgori, A.
 2006
 36 S2 p. S5-
1 p.
 article
162 O.023 Transfusion associated hepatitis B virus infections Holland, P.V.
 2006
 36 S2 p. S7-
1 p.
 article
163 O.208 Treatment of chronic HBV - optimization of the mean results by individualized viral kinetics analysis Neumann, A.U.
 2006
 36 S2 p. S59-S60
2 p.
 article
164 O.048 Treatment of chronic hepatitis B with the combination of pegylated interferon with a nucleoside/nucleotide analogue Marcellin, P.
 2006
 36 S2 p. S15-
1 p.
 article
165 O.152 Treatment of chronic hepatitis D Farci, P.
 2006
 36 S2 p. S47-
1 p.
 article
166 O.176 Treatment of HBV cirrhotics before transplantation Mutimer, D.
 2006
 36 S2 p. S54-
1 p.
 article
167 O.073 Treatment of HBV resistance Buti, M.
 2006
 36 S2 p. S22-
1 p.
 article
168 O.046 Treatment of hepatitis B e antigen positive disease Lau, G.K.K.
 2006
 36 S2 p. S14-S15
2 p.
 article
169 O.047 Treatment paradigms in hepatitis B e antigen negative (HBeAg-negative) chronic hepatitis B patients Hadziyannis, S.J.
 2006
 36 S2 p. S15-
1 p.
 article
170 O.139 Two types of histologically normal liver can have different gene expression patterns: The importance of an adequate normal tissue control in gene expression studies Asselah, T.
 2006
 36 S2 p. S43-
1 p.
 article
171 O.026 Vaccination against hepatitis B in liver transplant recipients with history of hepatitis B infection: analysis of cellular immune response shows evidence of HBsAg specific regulatory T cells Bauer, T.
 2006
 36 S2 p. S8-
1 p.
 article
172 O.078 Valopicitabine (NM283) plus peg-interferon for chronic hepatitis C in treatment naïve and nonresponder patients: interim phase IIb results Sherman, K.E.
 2006
 36 S2 p. S24-
1 p.
 article
173 O.119 Variability and diagnosis of hepatitis B virus Gerlich, W.H.
 2006
 36 S2 p. S36-
1 p.
 article
174 O.111 Viral and host factors in hepatitis B virus CCC DNA formation Gao, W.
 2006
 36 S2 p. S33-
1 p.
 article
175 O.059 Viral quasispecies evolution in chronic hepatitis B: new light on an old story Lim, S.G.
 2006
 36 S2 p. S18-
1 p.
 article
176 O.173 Virus-host interactions during the first steps of viral infection: host cell responses induced by cellular binding of hepatitis C virus-like particles Zeisel, M.B.
 2006
 36 S2 p. S53-
1 p.
 article
177 P.372 Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus-X Lee, Y.I.
 2006
 36 S2 p. S175-
1 p.
 article
178 P.494 A case-control of epidemiological status of hepatitis B positive cases among Shirazian blood donors in 2005 Kasraian, L.
 2006
 36 S2 p. S213-
1 p.
 article
179 P.179 A cell-based assay for evaluating potential antiviral agents against HCV Aviel, S.
 2006
 36 S2 p. S116-
1 p.
 article
180 P.178 Activation of endoplasmic reticulum stress signaling by the hepatitis C virus NS2 protein in the context of HCV replication Von dem Bussche, A.
 2006
 36 S2 p. S115-S116
2 p.
 article
181 P.204 Acute HCV infection in haemodialysis patients infected with the same virus strain varies in CD4 T-cell response and viral kinetics Weseslindtner, L.
 2006
 36 S2 p. S124-
1 p.
 article
182 P.415 Acute hepatitis B in HIV patients: risk and prevention of chronicity Miailhes, P.
 2006
 36 S2 p. S189-
1 p.
 article
183 P.060 Acute infection of woodchucks with californian and arctic ground squirrel hepatitis virus Glebe, D.
 2006
 36 S2 p. S79-
1 p.
 article
184 P.503 Advance and treatment features in patients with viral hepatitis and vasculitis Bezna, M.
 2006
 36 S2 p. S215-S216
2 p.
 article
185 P.475 A further definition of the major consequences of chronic hepatitis B in Venezuela Leon, R.V.
 2006
 36 S2 p. S208-
1 p.
 article
186 P.141 A large-scale evaluation of a new method for hepatitis C virus (HCV) genotyping based on real-time PCR González, V.
 2006
 36 S2 p. S104-
1 p.
 article
187 P.161 Alpha-glucosidase inhibitors prevent the assembly and induce a reduction of HCV infectivity Chapel, C.
 2006
 36 S2 p. S110-
1 p.
 article
188 P.170 Amantadine inhibits the function of an ion channel encoded by GB virus-B but fails to inhibit virus replication Dong, X.
 2006
 36 S2 p. S113-
1 p.
 article
189 P.083 A mathematical model for adefovir dipivoxil anti-HBV infection treatment Su, Y.
 2006
 36 S2 p. S86-
1 p.
 article
190 P.218 Analysis of immune response directed against hepatitis C virus (HCV) envelope glycoproteins during the natural history of HCV infection Esteban, L.
 2006
 36 S2 p. S129-
1 p.
 article
191 P.270 Analysis of interferon based therapy response in patients infected with hepatitis C genotype 1 and 3 virus Jardim, A.G.
 2006
 36 S2 p. S145-S146
2 p.
 article
192 P.011 Analysis of predicted RNA secondary structure of mutated hepatitis B virus encapsidation signals Ingman, M.
 2006
 36 S2 p. S64-
1 p.
 article
193 P.024 Analysis of surface promoter mutants of HBV: its relation to hepatitis B surface antigen production and secretion Sengupta, S.
 2006
 36 S2 p. S68-
1 p.
 article
194 P.015 Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particles assembly and infectivity Blanchet, M.
 2006
 36 S2 p. S65-S66
2 p.
 article
195 P.185 Analysis of the 5′UTR of in vitro replicated human hepatitis C virus Revie, D.
 2006
 36 S2 p. S118-
1 p.
 article
196 P.027 Analysis on early steps of infection of hepatitis B virus (HBV) by vesicular stomatitis virus (VSV) pseudotypes Saha, M.N.
 2006
 36 S2 p. S69-
1 p.
 article
197 P.339 A nasal vaccine candidate for chronic hepatitis B immunotherapy: from preclinical studies to phase I Muzio, V.L.
 2006
 36 S2 p. S165-
1 p.
 article
198 P.043 An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection Huang, L.R.
 2006
 36 S2 p. S74-
1 p.
 article
199 P.139 An international external quality assessment scheme for hepatitis C virus genotyping Read, S.
 2006
 36 S2 p. S103-
1 p.
 article
200 P.072 An outbreak of acute hepatitis B in a residential nursing home Kirkpatrick, A.
 2006
 36 S2 p. S83-
1 p.
 article
201 P.159 A novel fluorescence-based protease assay using the endogenous NS3/4A protease activity present in the total cell lysates of HCV replicon cells Yang, H.
 2006
 36 S2 p. S109-S110
2 p.
 article
202 P.152 Anti-HCV IgG avidity index in acute hepatitis C Coppola, N.
 2006
 36 S2 p. S107-S108
2 p.
 article
203 P.140 Anti-HCV immune response in healthy individuals in contact with chronic HCV carriers Znoiko, O.
 2006
 36 S2 p. S103-S104
2 p.
 article
204 P.291 Anti-HCV positive patients with end stage renal disease (ESRD): assessment of liver disease before and after kidney transplantation (KT) D'Aloiso, C.M.
 2006
 36 S2 p. S152-
1 p.
 article
205 P.150 Anti-HCV profile in serum specimens from HCV infected patients coinfected with opportunistic diseases Bochkova, G.B.
 2006
 36 S2 p. S107-
1 p.
 article
206 P.292 Antinuclear antibody (ANA) positivity in patients with chronic hepatitis C: clinically relevant or merely an epiphenomenon? Narciso, J.L.
 2006
 36 S2 p. S153-
1 p.
 article
207 P.113 Anti-viral activity, histologic improvement and safety of entecavir in Japanese adult nucleoside-analogue naive patients with chronic hepatitis B infection: a phase 2 clinical trial Takaguchi, K.
 2006
 36 S2 p. S96-
1 p.
 article
208 P.262 Antiviral treatment for hepatitis C virus (HCV) infection: effectiveness in the general population of a highly endemic area Caserta, C.A.
 2006
 36 S2 p. S143-
1 p.
 article
209 P.213 Apoptosis in acute and chronic experimental HCV infection Choi, Y.H.
 2006
 36 S2 p. S127-
1 p.
 article
210 P.359 Apoptotic caspase activation in sera from patients with chronic hepatitis C (CH-C), chronic hepatitis B (CH-B) or non-alcoholic steatohepatitis (NASH) Papatheodoridis, G.V.
 2006
 36 S2 p. S171-
1 p.
 article
211 P.050 Appearance of core antigen negative hepatocytes in woodchucks chronically infected with woodchuck hepatitis virus Xu, C.
 2006
 36 S2 p. S76-
1 p.
 article
212 P.279 A randomised trial of pegylated interferon alpha-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin Ciancio, A.
 2006
 36 S2 p. S148-
1 p.
 article
213 P.422 A risk score for predicting non-alcoholic steatohepatitis in patients undergoing liver biopsy Nachnani, J.S.
 2006
 36 S2 p. S191-
1 p.
 article
214 P.278 A side effect rarely seen on chronic hepatitis C treatment with PEG-IFN and ribavirin: alopecia universalis Aykin, N.
 2006
 36 S2 p. S148-
1 p.
 article
215 P.228 Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus RNA load upon therapy Chevaliez, S.
 2006
 36 S2 p. S132-
1 p.
 article
216 P.508 Assessment of the safety of injections and related medical practices in health institutions at Sidama Zone, SNNPRS Gebriel, Y.G.W.
 2006
 36 S2 p. S217-
1 p.
 article
217 P.293 Assessment of viral loads in patients with chronic hepatitis C: influence of HCV genotypes on quantification assays Aguilera, A.
 2006
 36 S2 p. S153-
1 p.
 article
218 P.205 Association between HCV infection and cardio-vascular risk factors in rural Egypt Marzouk, D.
 2006
 36 S2 p. S124-S125
2 p.
 article
219 P.019 Association of HBV precore protein with P32/gC1qR modulates apoptosis Assrir, N.
 2006
 36 S2 p. S67-
1 p.
 article
220 P.037 Association of hepatitis B virus surface gene mutations with viral genotypes in patients with occult HBV infection Kumar, T.G.
 2006
 36 S2 p. S72-
1 p.
 article
221 P.215 Association of toll-like receptor gene 3 C6300T polymorphisms with inflammatory activity and liver cirrhosis in chronic hepatitis C virus infection Li, Q.
 2006
 36 S2 p. S128-
1 p.
 article
222 P.496 A survey of epidemiological status of hepatitis C infection among Shirazian blood donors in 2005 Kasraian, L.
 2006
 36 S2 p. S214-
1 p.
 article
223 P.308 A tryptophan-rich motif in the carboxyl-terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles Komla-Soukha, I.
 2006
 36 S2 p. S157-
1 p.
 article
224 P.254 Australian trial in acute hepatitis C: baseline behavioural data Hellard, M.
 2006
 36 S2 p. S140-
1 p.
 article
225 P.250 Australian trial in acute hepatitis C: preliminary findings Hellard, M.
 2006
 36 S2 p. S139-
1 p.
 article
226 P.209 Autoantibody response to a drug-metabolizing enzyme, microsomal epoxide hydrolase in hepatitis C and A Akatsuka, T.
 2006
 36 S2 p. S126-
1 p.
 article
227 P.272 Autoimmune thrombocytopenia induced by peg-IFN alpha-2b plus ribavirin in hepatitis C Cevik, F.
 2006
 36 S2 p. S146-
1 p.
 article
228 P.358 Autotaxin and lysophosphatidic acid in the blood in patients of viral hepatitis Watanabe, N.
 2006
 36 S2 p. S171-
1 p.
 article
229 P.035 Basal core promoter, precore region mutations of HBV and their association with e antigen status, genotype, and severity of liver disease in chronic hepatitis B patients in India Sarin, S.K.
 2006
 36 S2 p. S72-
1 p.
 article
230 P.197 Baseline neutralizing responses predict the virological response to pegylated interferon alpha-ribavirin combination therapy Woerther, P.
 2006
 36 S2 p. S121-S122
2 p.
 article
231 P.450 Bayesian coalescent inference of hepatitis C virus introduction from molecular sequences: the Camporeale model Argentini, C.
 2006
 36 S2 p. S200-
1 p.
 article
232 P.189 Bayesian networks for evaluation of dependencies between epidemiological, virological and molecular features of the hepatitis C virus infections Lara, J.
 2006
 36 S2 p. S119-
1 p.
 article
233 P.501 Biochemical and proteomic characterization of very low-density/low-density lipoproteins from blood donors infected with hepatitis C virus (HCV) or hepatitis B virus (HBV) sun, H.Y.
 2006
 36 S2 p. S215-
1 p.
 article
234 P.365 Biochemical markers of liver fibrosis and activity in patients with chronic hepatitis C and mixed cryoglobulinemia systemic vasculitis Sène, D.
 2006
 36 S2 p. S173-
1 p.
 article
235 P.237 Blood distribution of non-phosphorylated and phosphorylated forms of ribavirin in patients treated for chronic hepatitis C Gagnieu, M.
 2006
 36 S2 p. S135-
1 p.
 article
236 P.184 CD4+, CD8+ and CD16+ T cell responses in patients with chronic HCV associated with herpes virus infection Adela, T.I.
 2006
 36 S2 p. S117-S118
2 p.
 article
237 P.347 Cellular immune response to a pres1/pres2 containing hepatitis B vaccine Schumann, A.
 2006
 36 S2 p. S167-S168
2 p.
 article
238 P.472 Change of seroprevalence of hepatitis B surface Ag and hepatitis C Ab among Egyptian young adults El Sahhar, M.
 2006
 36 S2 p. S207-
1 p.
 article
239 P.160 Characterisation and inhibition of the enzymatic activity of genotype 3a polymerase White, P.A.
 2006
 36 S2 p. S110-
1 p.
 article
240 P.123 Characterisation of a mouse monoclonal and rabbit polyclonal antibody against the hepatitis B precore protein Rodgers, S.C.
 2006
 36 S2 p. S98-
1 p.
 article
241 P.023 Characterisation of an adefovir resistant HBV strain with truncated surface proteins and a severe secretion defect Warner, N.
 2006
 36 S2 p. S68-
1 p.
 article
242 P.001 Characterization of occult HBV carriers according to a retrospective longitudinal follow-up of 26 patients Guillaud, O.
 2006
 36 S2 p. S61-
1 p.
 article
243 P.331 Characterization of recombinant virus-like particles of genotype 3 hepatitis E virus Li, T.
 2006
 36 S2 p. S163-
1 p.
 article
244 P.075 Chronic hepatitis B (CHB) management costs in Sweden De Cock, E.
 2006
 36 S2 p. S84-
1 p.
 article
245 P.488 Chronic hepatitis C in injecting drug users: a comparison with non-injecting drug users in the same geographic area Price, D.A.
 2006
 36 S2 p. S212-
1 p.
 article
246 P.298 Chronic hepatitis C — no influence of different activity status on the quality of life Wiese, M.
 2006
 36 S2 p. S154-
1 p.
 article
247 P.173 Clinical and therapeutic implications of HCV compartmentalization Di Liberto, G.
 2006
 36 S2 p. S114-
1 p.
 article
248 P.403 Clinical and virological improvement of HBV or HCV related chronic hepatitis with concomitant HAV infection Sagnelli, E.
 2006
 36 S2 p. S185-
1 p.
 article
249 P.414 Clinical course of chronic hepatitis in HCV/HIV coinfected patients: the lesson from sequential liver biopsies Sagnelli, C.
 2006
 36 S2 p. S188-S189
2 p.
 article
250 P.504 Clinical features of Wilson's disease in Sardinia Murru, A.
 2006
 36 S2 p. S216-
1 p.
 article
251 P.371 Clinical profiles of chronic schistosomiasis mansoni Egyptian patients with and without hepatitis C infection Hussein, E.M.
 2006
 36 S2 p. S175-
1 p.
 article
252 P.003 Clinical relevance of the COBAS TaqMan HBV assay Martinot-Peignoux, M.
 2006
 36 S2 p. S61-S62
2 p.
 article
253 P.420 Coinfection HIV/HCV - report of 26 treated patients Valente, C.
 2006
 36 S2 p. S190-S191
2 p.
 article
254 P.203 Colocalization of HCV core protein with intracellular lipid droplets occurs regardless of the HCV genotype and the steatogenic character of HCV strains Piodi, A.
 2006
 36 S2 p. S124-
1 p.
 article
255 P.263 Combination of interferon and ribavirin in the treatment of dialysis patients with chronic hepatitis C Fernandes, S.
 2006
 36 S2 p. S143-S144
2 p.
 article
256 P.115 Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment previously Hissar, S.S.
 2006
 36 S2 p. S96-S97
2 p.
 article
257 P.356 Combination therapy with antiviral drugs and immunomodulation against chronic hepatitis B virus infection: evaluation in the woodchuck model Lu, M.
 2006
 36 S2 p. S170-
1 p.
 article
258 P.348 Comparative evaluation of three different commercial assays for quantitation of anti-HBs levels after immunization with recombinant vaccines Miguel, J.C.
 2006
 36 S2 p. S168-
1 p.
 article
259 P.430 Comparative pathogenesis of viral hepatitis Purcell, R.H.
 2006
 36 S2 p. S194-
1 p.
 article
260 P.153 Comparison of the HCV genotypes between active drug users and patients in therapeutic process in the Slovak Republic in the years 2004–2005 Koncova-Fejdiova, K.
 2006
 36 S2 p. S108-
1 p.
 article
261 P.266 Comparison of therapeutic results on HCV and HCV/HIV co-infected patients Serra, J.E.
 2006
 36 S2 p. S144-
1 p.
 article
262 P.346 Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers Wouters, K.
 2006
 36 S2 p. S167-
1 p.
 article
263 P.200 Comprehensive analysis of IFN-γ and IL-2 production by T cells in acute and chronic HCV infection Ffrench, R.A.
 2006
 36 S2 p. S123-
1 p.
 article
264 P.034 Construction of hepatitis B surface antigen vectors using natural restriction sites located within or around the hydrophilic a determinant region: development of chimeric plasmids containing the HVR1 of hepatitis C virus E2 protein Araujo, N.M.
 2006
 36 S2 p. S71-
1 p.
 article
265 P.379 Contrast-enhanced ultrasonography allows a real-time help for assessment of percutaneous radiofrequency ablation efficacy of hepatocellular carcinoma Beziat, C.
 2006
 36 S2 p. S177-
1 p.
 article
266 P.137 Correlation between hepatitis B virus genotype and HBV DNA level in chronic hepatitis B patients Mahtab, M.A.
 2006
 36 S2 p. S102-S103
2 p.
 article
267 P.162 Cross-immunoreactivity between hepatitis C virus hypervariable region 1 variants as modeled with synthetic peptides Yokosawa, J.
 2006
 36 S2 p. S111-
1 p.
 article
268 P.455 Current epidemiological characteristic of viral hepatitis B and C in Russian Federation Schakhguildyan, I.V.
 2006
 36 S2 p. S202-
1 p.
 article
269 P.487 Current patterns of hepatitis C viral infection in the Republic of Georgia Ninashvili, N.Z.
 2006
 36 S2 p. S211-S212
2 p.
 article
270 P.030 C1858 was specific in HBV genotype C in patients from northern Vietnam but not in Japanese patients Truong, B.X.
 2006
 36 S2 p. S70-
1 p.
 article
271 P.452 Decline in the prevalence of hepatitis B virus infection amongst healthy pregnant women in India — the changed scenario Sarin, S.K.
 2006
 36 S2 p. S201-
1 p.
 article
272 P.499 Declining prevalence of HCV infection among injection drug users from Rio de Janeiro, Brazil: a comparative analysis of two cross-sectional surveys Oliveira, M.L.A.
 2006
 36 S2 p. S214-S215
2 p.
 article
273 P.261 Decrease of leukocytes count as a prognostic factor of treatment response in children with chronic hepatitis C treated with IFN-alpha and ribavirin Pawlowska, M.
 2006
 36 S2 p. S143-
1 p.
 article
274 P.057 Defective recognition of viral mutants by CD4+ T cells specific for a promiscuous HBx-derived epitope in HBV chronic carriers Malmassari, S.L.
 2006
 36 S2 p. S78-
1 p.
 article
275 P.093 Demonstration of a firm association between detection of IgG antibody reactivity towards the C-terminal part of the pres1 protein of HBV and the capacity to respond to interferon therapy in chronic hepatitis B Hellstrom, U.B.
 2006
 36 S2 p. S90-
1 p.
 article
276 P.355 Dendritic cells expressing hepatitis C virus (HCV) derived antigens NS3 or Core: phenotype, antigen presentation and T cell stimulation Agrawal, B.
 2006
 36 S2 p. S170-
1 p.
 article
277 P.327 Detection and characterization of hepatitis A virus RNA in fulminant hepatic failure in children in Argentina Munne, M.S.
 2006
 36 S2 p. S162-
1 p.
 article
278 P.332 Detection and characterization of hepatitis E virus RNA in three fulminant hepatic failure cases in children in Argentina Munne, M.S.
 2006
 36 S2 p. S163-
1 p.
 article
279 P.304 Detection of HEV antigen in serum as a new marker for diagnosis of hepatitis E Zhang, F.
 2006
 36 S2 p. S155-S156
2 p.
 article
280 P.309 Development and validation of rapid, point-of-care tests for acute hepatitis E virus Infection Anderson, D.A.
 2006
 36 S2 p. S157-
1 p.
 article
281 P.148 Development of a novel immunoassay for ultra-sensitive oral diagnosis of hepatitis C virus O'Brien, S.
 2006
 36 S2 p. S106-
1 p.
 article
282 P.315 Development of bicistronic selectable vector for non-radioactive antigen specific reporter release T cell cytotoxicity assay Tayal, R.
 2006
 36 S2 p. S158-
1 p.
 article
283 P.319 Development of small interfering RNAs (siRNAs/shRNAs) for inhibition of hepatitis E virus (HEV) replication and transcription Kar, U.K.
 2006
 36 S2 p. S159-
1 p.
 article
284 P.469 Diabetes is associated with chronic liver disease and liver cancer in the adult population of Puerto Rico Ortiz, A.P.
 2006
 36 S2 p. S206-
1 p.
 article
285 P.047 Diagnostic accuracy of MP3 score compared to hyaluronate and fibrotest for evaluating liver fibrosis in chronic hepatitis B Hilleret, M.
 2006
 36 S2 p. S75-
1 p.
 article
286 P.285 Differences in virus and host characteristics between patients with HCV genotype 2 or 3 participating in a large international study Zeuzem, S.
 2006
 36 S2 p. S150-
1 p.
 article
287 P.038 Differences of ymdd mutational patterns, pre-core/core promoter mutations, serum viral loads in lamivudine-resistant hepatitis B genotypes B and C Li, L.J.
 2006
 36 S2 p. S72-
1 p.
 article
288 P.432 Differential expression profiling and target genes studies of hepatic differentiation and carcinogensis Tung, C.
 2006
 36 S2 p. S194-S195
2 p.
 article
289 P.374 Different mechanisms are involved in N-myc2 activation in WHV hepatocarcinogenesis Bruni, R.
 2006
 36 S2 p. S176-
1 p.
 article
290 P.146 Different stratification of HCV viral load as high/low in pre IFN-RBV treatment samples according to the commercial method used Fay, F.F.
 2006
 36 S2 p. S105-S106
2 p.
 article
291 P.192 Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies Baumann, K.
 2006
 36 S2 p. S120-
1 p.
 article
292 P.281 Diversity of type 2 hepatitis C virus strains in France Cantaloube, J.
 2006
 36 S2 p. S149-
1 p.
 article
293 P.385 DNA-repair and carcinogen-metabolizing enzymes genetic polymorphisms in a population of liver transplanted patients with or without hepatocellular carcinoma Borentain, P.
 2006
 36 S2 p. S179-
1 p.
 article
294 P.199 Dominant and subdominant T-cell responses and viral evolution in subjects with acute symptomatic HCV infection Nolan, B.
 2006
 36 S2 p. S122-
1 p.
 article
295 P.104 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) Chang, T.T.
 2006
 36 S2 p. S93-
1 p.
 article
296 P.212 Early evolution of hepatitis C virus quasispecies and immunologic factors during HCV recurrence after liver transplantation for HCV-related disease Schvoerer, E.
 2006
 36 S2 p. S127-
1 p.
 article
297 P.271 Early HCV viral load determination as a predictive parameter of the response to the antiviral therapy in HCV infected patients Payan, C.
 2006
 36 S2 p. S146-
1 p.
 article
298 P.273 Early results of peg-IFN α-2a treatment in chronic hemodialysis patients with chronic c hepatitis Strain, M.H.
 2006
 36 S2 p. S146-S147
2 p.
 article
299 P.235 Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement Payan, C.
 2006
 36 S2 p. S134-
1 p.
 article
300 P.274 Echinococcosis granulosus and hepatitis C infection in liver with major depression: a case report Akhan, S.
 2006
 36 S2 p. S147-
1 p.
 article
301 P.489 Educating primary care providers about hepatitis C Winston, D.H.
 2006
 36 S2 p. S212-
1 p.
 article
302 P.277 Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD): a randomized, controlled pilot study Quarentini, L.
 2006
 36 S2 p. S148-
1 p.
 article
303 P.109 Efficacy and safety of entecavir and lamivudine in japanese adult patients with chronic hepatitis B infection: a phase 2 clinical trial Shindo, M.
 2006
 36 S2 p. S94-S95
2 p.
 article
304 P.086 Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B Senturk, H.
 2006
 36 S2 p. S87-
1 p.
 article
305 P.349 Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma in Long An county, Guangxi Province, China Li, R.
 2006
 36 S2 p. S168-
1 p.
 article
306 P.352 Efficacy of hepatitis B vaccine in preventing clinical hepatitis B in children: a 13 years follow-up Gong, J.
 2006
 36 S2 p. S169-
1 p.
 article
307 P.353 Efficiency of HBV vaccination for healthcare workers Tanomand, A.
 2006
 36 S2 p. S169-
1 p.
 article
308 P.232 Egyptian patients have better sustained response and more rapid drop of HCV RNA level than non-Egyptian patients with HCV genotype 4 El Ray, A.
 2006
 36 S2 p. S133-
1 p.
 article
309 P.410 Enhanced activation of IFN system by GBV-C in HIV co-infected subjects Lalle, E.
 2006
 36 S2 p. S187-
1 p.
 article
310 P.090 Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022) De Man, R.A.
 2006
 36 S2 p. S89-
1 p.
 article
311 P.082 Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg(-) chronic hepatitis B patients (study ETV-027) Manns, M.
 2006
 36 S2 p. S86-
1 p.
 article
312 P.110 Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: phase II/III safety results Raptopoulou Gigi, M.
 2006
 36 S2 p. S95-
1 p.
 article
313 P.089 Entecavir results in a rapid reduction in viral load in chronic hepatitis B patients who have failed lamivudine therapy: a randomized, placebo-controlled study in China Yao, G.
 2006
 36 S2 p. S88-
1 p.
 article
314 P.473 Epidemiological and clinical characterization of patients infected with hepatitis C virus genotype 4 in Portugal Gloria, H.
 2006
 36 S2 p. S207-S208
2 p.
 article
315 P.009 Epidemiological characteristics of HBV inactive chronic carriers and comparison with hbe antigen negative chronic hepatitis B patients Zarski, J.
 2006
 36 S2 p. S63-S64
2 p.
 article
316 P.484 Epidemiological characterization of chronic hepatitis C in Portugal Areias, J.
 2006
 36 S2 p. S211-
1 p.
 article
317 P.492 Epidemiological study of the hepatitis C virus transmission routes associated to genotyping Jardim, A.G.
 2006
 36 S2 p. S213-
1 p.
 article
318 P.135 Epidemiology of HBV infection in Luanda (Angola) — preliminary results Constantino, A.F.M.
 2006
 36 S2 p. S102-
1 p.
 article
319 P.389 Epidemiology of hepatocellular carcinoma in Morocco Benjelloun, S.
 2006
 36 S2 p. S181-
1 p.
 article
320 P.433 Epigenetic down-regulation of death-associated protein kinase in hepatocellular carcinoma Chen, C.
 2006
 36 S2 p. S195-
1 p.
 article
321 P.138 Evaluation of a new, non-invasive marker for fibrosis (FIB-4) in a large series of patients infected by the hepatitis C virus alone Vallet-Pichard, A.
 2006
 36 S2 p. S103-
1 p.
 article
322 P.240 Evaluation of fibrosis regression using fibroscan in HCV responder patients. A prospective controlled study De Ledinghen, V.
 2006
 36 S2 p. S136-
1 p.
 article
323 P.368 Evaluation of neuropsychical syndromes in hepatic encephalopathy Tanasie, M.M.
 2006
 36 S2 p. S174-
1 p.
 article
324 P.444 Evaluation of the hepatitis B vaccination program targeted towards high-risk groups in Amsterdam, the Netherlands Van Houdt, R.
 2006
 36 S2 p. S198-
1 p.
 article
325 P.142 Evaluation of the sensitivity of the enhanced ARCHITECT anti-HCV assay on well characterized samples from early seroconversion and seroreversion Echevarrfa, J.M.
 2006
 36 S2 p. S104-
1 p.
 article
326 P.132 Evaluation of the vaccinal hepatitis B status of hemodialysis patients in a university hospital Góngora, D.V.N.
 2006
 36 S2 p. S101-
1 p.
 article
327 P.008 Evaluation of VIKIA® HBsAg, a new immuno-chromatographic test for the qualitative detection of HBs antigen in serum, plasma and whole blood human samples Marcillat, S.
 2006
 36 S2 p. S63-
1 p.
 article
328 P.394 Evaulation of bone marrow derived stem cells in hepatocyte regeneration in patients with end-stage liver disease Amin, M.A.
 2006
 36 S2 p. S182-
1 p.
 article
329 P.032 Evolution of hepatitis B virus diversity in French blood donors through a seven-year survey Laperche, S.
 2006
 36 S2 p. S71-
1 p.
 article
330 P.062 Excess mortality associated with chronic hepatitis B virus infection: the R.E.V.E.A.L.-HBV study Iloeje, U.H.
 2006
 36 S2 p. S80-
1 p.
 article
331 P.506 Experimental vaccination of marmosets against GBV-B infection Kyuregyan, K.
 2006
 36 S2 p. S217-
1 p.
 article
332 P.164 Expression of the ARFP/F/core+1 protein from HCV-1b clinical isolates Boumlic, A.
 2006
 36 S2 p. S111-
1 p.
 article
333 P.290 Extra-hepatic cancer incidence among patients with hepatitis C virus infection. A cohort study Tosti, M.E.
 2006
 36 S2 p. S152-
1 p.
 article
334 P.080 Fatal hepatic failure of a chronic hepatitis B patient several months after the emergence of lamivudine resistant mutations Bottecchia, M.
 2006
 36 S2 p. S85-
1 p.
 article
335 P.392 Fibrosis progression after liver transplantation in patients with recurrent hepatitis C Walter, T.
 2006
 36 S2 p. S181-
1 p.
 article
336 P.105 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in hepatitis B e antigen-negative patients Borroto-Esoda, K.
 2006
 36 S2 p. S93-
1 p.
 article
337 P.163 Forces driving viral sequence evolution in acute hepatitis C infection Kuntzen, T.
 2006
 36 S2 p. S111-
1 p.
 article
338 P.380 Four-dimensional ultrasonography for therapeutic radiofrequency ablation for hepatocellular carcinoma Hotta, N.
 2006
 36 S2 p. S178-
1 p.
 article
339 P.434 Frizzled-7 is commonly expressed by cancerous hepatocytes in virus and non-virus related human hepatocellular carcinomas: correlations with pathological features and β-catenin/p53 mutation status De Souza, M.M.
 2006
 36 S2 p. S195-
1 p.
 article
340 P.172 Functional comparison of the antagonism of hepatitis C virus genotype 1b and 2a nonstructural protein 5a to interferon antiviral activity Tsai, Y.
 2006
 36 S2 p. S114-
1 p.
 article
341 P.373 Fusion mRNA from HBV integrants in human hepatoma cell line is associated with hepatocellular carcinogenesis Muroyama, R.
 2006
 36 S2 p. S175-S176
2 p.
 article
342 P.243 Gene expression profile in PBMC exposed to IFN-alpha in vitro as a predictor of treatment response for HCV-infected patients Calcaterra, S.
 2006
 36 S2 p. S137-
1 p.
 article
343 P.466 Genetic characterization of hepatitis C virus strains from Estonia Tallo, T.
 2006
 36 S2 p. S205-
1 p.
 article
344 P.245 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non-responders to standard combination therapy Moukari, R.
 2006
 36 S2 p. S137-S138
2 p.
 article
345 P.299 Genotype 5 hepatitis C virus: a rare case in Brazil Manzoni, E.M.M.
 2006
 36 S2 p. S154-S155
2 p.
 article
346 P.073 Genotypification of hepatitis B virus in patients from endemic areas in Peru Hijar, G.G.
 2006
 36 S2 p. S83-
1 p.
 article
347 P.143 Genotyping hepatitis C virus in South Africa: a comparison of results obtained by partial sequencing of the 5UTR and NS5B regions with a real-time lightcycler genotyping method Prabdial-Sing, N.
 2006
 36 S2 p. S104-S105
2 p.
 article
348 P.344 Global hepatitis B immunization - status Wiersma, S.T.
 2006
 36 S2 p. S167-
1 p.
 article
349 P.127 Haematopoietic stem cell transplantation in patients with resolved hepatitis B: HBV reactivation in a recipient of stem cells from a donor vaccinated against HBV Knöll, A.
 2006
 36 S2 p. S100-
1 p.
 article
350 P.029 HBeAg defective mutants in active/inactive anti-HBe positive HBV carriers: possible role of pre-core initiation mutants Flichman, D.
 2006
 36 S2 p. S70-
1 p.
 article
351 P.124 HBV immunization, post-immunization serology and immunity among healthcare workers in Canada McCarthy, G.M.
 2006
 36 S2 p. S98-S99
2 p.
 article
352 P.004 HBV molecular epidemiology in Dakar, Senegal Simon, F.M.
 2006
 36 S2 p. S62-
1 p.
 article
353 P.063 HBV reactivation in HBsAg-negative patients undergoing chemotherapy for haematological malignancies Colson, P.
 2006
 36 S2 p. S80-
1 p.
 article
354 P.354 HBV specific acyclic pyrimidine nucleosides: synthesis and anti-HBV activity of 5- and/or 6-substituted analogs of 1-[(2-hydroxyethoxy)methyl] uracils Kumar, R.
 2006
 36 S2 p. S170-
1 p.
 article
355 P.007 HBV viral load in renal transplant patients: the impact of HBV-HCV co-infection in HBV-DNA levels Matos, C.A.
 2006
 36 S2 p. S63-
1 p.
 article
356 P.442 HCV and HIV seroprevalences and at-risk behaviors among drug users, ANRS-Coquelicot study, France, 2004 Jauffret-Roustide, M.
 2006
 36 S2 p. S197-S198
2 p.
 article
357 P.429 HCV core protein activates peroxisome proliferator-activated receptor gamma (PPARγ) in human monocytes and regulates gene expression involved in M2 polarisation Balard, P.
 2006
 36 S2 p. S193-S194
2 p.
 article
358 P.166 HCV core protein interacts with β-tubulin and inhibits tubulin polymerisation Roohvand, F.
 2006
 36 S2 p. S112-
1 p.
 article
359 P.190 HCV core variants isolated from liver tumor interact with Smad3 and inhibit the TGF-β pathway Battaglia, S.
 2006
 36 S2 p. S119-
1 p.
 article
360 P.405 HCV/HIV co-infected drug users are at increased risk to die from hepatitis related causes in the era of effective HIV therapy, compared to HCV mono-infected drug users Smit, C.
 2006
 36 S2 p. S185-S186
2 p.
 article
361 P.183 HCV NS5A protein and response to IFN α: mutational analysis in 3a genotype chronic hepatitis C patients from India Goyal, A.
 2006
 36 S2 p. S117-
1 p.
 article
362 P.256 HCV relapse in sustained responders to interferon therapy for chronic hepatitis C genotype 4 El-Raziky, M.
 2006
 36 S2 p. S141-
1 p.
 article
363 P.388 HCV-related hepatocellular carcinoma in non-cirrhotic liver: immunohistochemical study of two cases Lázari, C.S.
 2006
 36 S2 p. S180-S181
2 p.
 article
364 P.226 HCV-related morbidity in a rural community of Egypt Mohamed, M.K.
 2006
 36 S2 p. S131-
1 p.
 article
365 P.193 HCV-specific immune responses in HCV-uninfected individuals Janvier, G.
 2006
 36 S2 p. S120-
1 p.
 article
366 P.229 HCV-1 subtypes and response to pegylated interferon plus ribavirin therapy Alberti, A.
 2006
 36 S2 p. S132-
1 p.
 article
367 P.265 HCV sustained virological response in 44 patients that were virological responders at week 4 Marques, N.M.S.
 2006
 36 S2 p. S144-
1 p.
 article
368 P.334 HDV genotypes in the western Brazilian Amazon region: a preliminary report Paraná, R.
 2006
 36 S2 p. S164-
1 p.
 article
369 P.302 Heat shock cognate protein 70 may mediate the entry of hepatitis E virus into host cells Zhou, Y.
 2006
 36 S2 p. S155-
1 p.
 article
370 P.282 Hepatic steatosis in genotype 4 chronic hepatitis C (CH-C) is mainly due to metabolic factors Tsochatzis, E.
 2006
 36 S2 p. S149-
1 p.
 article
371 P.401 Hepatic steatosis in HIV and hepatitis C virus coninfected patients receiving antiretroviral therapy Martinez, V.
 2006
 36 S2 p. S184-
1 p.
 article
372 P.316 Hepatitis A infection in Naples and Caserta areas during the period 2000–2004: is the virus normally circulating or it has been re-introduced? Genovese, D.
 2006
 36 S2 p. S158-S159
2 p.
 article
373 P.491 Hepatitis and health policies in Greece Christodoulou, I.O.
 2006
 36 S2 p. S212-S213
2 p.
 article
374 P.314 Hepatitis A virus in environmental water samples from Amazon Basin De Paula, V.S.
 2006
 36 S2 p. S158-
1 p.
 article
375 P.338 Hepatitis B vaccine induces cellular immune responses in most humoral non-responders Bauer, T.
 2006
 36 S2 p. S165-
1 p.
 article
376 P.486 Hepatitis B viral markers on 2036 previously infected individuals Hasanjani Roushan, M.R.
 2006
 36 S2 p. S211-
1 p.
 article
377 P.077 Hepatitis B virus genotype C is associated with more severe liver disease than genotype D in chronic hepatitis B patients in Bangladesh Mahtab, M.A.
 2006
 36 S2 p. S84-S85
2 p.
 article
378 P.068 Hepatitis B virus genotypes: a retrospective study in aquitaine (southwestern France) Trimoulet, P.
 2006
 36 S2 p. S82-
1 p.
 article
379 P.051 Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation Viganó, M.
 2006
 36 S2 p. S76-
1 p.
 article
380 P.054 Hepatitis B virus vaccine escape mutants may have defects in virion secretion Kwei, K.
 2006
 36 S2 p. S77-
1 p.
 article
381 P.048 Hepatitis B virus X protein mediates mitotic abnormalities and polyploidy via p53 deregulation and DNA re-replication Rakotomalala, L.
 2006
 36 S2 p. S75-S76
2 p.
 article
382 P.022 Hepatitis B virus x protein overcomes oncogene-induced senescense with active H-Ras-V12 in human immortal cells Oishi, N.
 2006
 36 S2 p. S68-
1 p.
 article
383 P.239 Hepatitis C antiviral therapy in cirrhotic patients Oliveira, P.R.D.
 2006
 36 S2 p. S135-S136
2 p.
 article
384 P.257 Hepatitis C genotype 4 in Belgium: a multicentric registry Hemmink, G.J.M.
 2006
 36 S2 p. S141-
1 p.
 article
385 P.222 Hepatitis C genotypes are related to slower histological lesions in chronic hepatitis C R-Viso, A.T.
 2006
 36 S2 p. S130-
1 p.
 article
386 P.468 Hepatitis C genotypic profile in 251 HIV/HCV co-infected patients in Puerto Rico Mayor, A.M.
 2006
 36 S2 p. S206-
1 p.
 article
387 P.286 Hepatitis C in former soccer players from 1950 to 1980 Joveleviths, D.
 2006
 36 S2 p. S150-S151
2 p.
 article
388 P.224 Hepatitis C: interfamilial or sexual transmission? Cavalheiro, N.P.
 2006
 36 S2 p. S131-
1 p.
 article
389 P.439 Hepatitis C mortality in the USA, 1995–2003 Wise, M.E.
 2006
 36 S2 p. S196-S197
2 p.
 article
390 P.151 Hepatitis C prevalence with normal serum alanine aminotransferase in a cohort analytical study of population referred to Iranian Red Crescent clinic in Azerbaijan Republic Farhadi, N.
 2006
 36 S2 p. S107-
1 p.
 article
391 P.400 Hepatitis C recurrence after liver transplantation agauE. Abdala Tonacio, A.C.
 2006
 36 S2 p. S184-
1 p.
 article
392 P.399 Hepatitis C recurrence in liver transplantation in University Hospital “Merkur”, Zagreb Colic Cvrlje, V.
 2006
 36 S2 p. S183-S184
2 p.
 article
393 P.242 Hepatitis C screening and treatment among drug users in Amsterdam: an interim analysis of the DUTCH-C project Lindenburg, K.
 2006
 36 S2 p. S136-S137
2 p.
 article
394 P.458 Hepatitis C screening in France from a laboratory based surveillance network (Rena-VHC): trends from 2000 to 2004 Meffre, C.
 2006
 36 S2 p. S203-
1 p.
 article
395 P.180 Hepatitis C virus (HCV) internal ribosome entry site (IRES) variants from serum, liver and PBMCs and their translational efficiency in different cell lines Hsieh, F.
 2006
 36 S2 p. S116-
1 p.
 article
396 P.451 Hepatitis C virus immunovirology in a social network of injecting drug users Hellard, M.
 2006
 36 S2 p. S200-S201
2 p.
 article
397 P.336 Hepatitis E virus infection in rural communities of southern China Li, R.C.
 2006
 36 S2 p. S164-
1 p.
 article
398 P.154 Hepatitis virus C RNA quantification by automated COBAS AmpliPrep-COBAS TaqMan 48 (CAP-CTM) real-time PCR assay: An evaluation of performance Chevaliez, S.
 2006
 36 S2 p. S108-
1 p.
 article
399 P.236 Hep573 study of complementary medicine for chronic hepatitis C Salmond, S.J.
 2006
 36 S2 p. S134-S135
2 p.
 article
400 P.087 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naive subjects during the first two years of therapy Colonno, R.J.
 2006
 36 S2 p. S87-S88
2 p.
 article
401 P.481 High prevalence of an unusual HCV subtype in a population of polytransfused patients El-Sayed, M.H.
 2006
 36 S2 p. S210-
1 p.
 article
402 P.198 High prevalence of broadly reactive HCV-specific cellular immune responses in antibody and PCR negative prisoners reporting injecting drug use Elliott, L.N.
 2006
 36 S2 p. S122-
1 p.
 article
403 P.480 High prevalence of genotype 2c hepatitis C virus in Córdoba, Argentina Ré, V.
 2006
 36 S2 p. S210-
1 p.
 article
404 P.416 High prevalence of mixed HBV genotypes in patients with HIV Shire, N.J.
 2006
 36 S2 p. S189-
1 p.
 article
405 P.217 High rate of spontaneous viral clearance in patients with symptomatic acute hepatitis C Licata, A.
 2006
 36 S2 p. S128-S129
2 p.
 article
406 P.238 High sustained virological response (SVR) rates with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in haemodialysed CHC patients awaiting renal transplant Rendina, M.
 2006
 36 S2 p. S135-
1 p.
 article
407 P.395 Histological benefit of retreatment by pegylated-IFN and ribavirin in patients with recurrent hepatitis HCV infection post-transplantation Bizollon, T.
 2006
 36 S2 p. S182-
1 p.
 article
408 P.393 Histological status of liver grafts after more than 10 years of follow-up: a study of 110 patients Chevallier, M.
 2006
 36 S2 p. S182-
1 p.
 article
409 P.118 Histologic improvement of the liver after one year of lamivudine therapy in anti-HBe positive chronic hepatitis B Hasanjani Roushan, M.R.
 2006
 36 S2 p. S97-
1 p.
 article
410 P.149 Histopathological characterization of genotype 4 chronic hepatitis C Esmat, G.
 2006
 36 S2 p. S106-S107
2 p.
 article
411 P.191 HLA-associated sequence polymorphisms in HCV reveal the reproducibility of immune responses and constraints on viral evolution Timm, J.
 2006
 36 S2 p. S119-S120
2 p.
 article
412 P.079 Hospital-induced hepatitis Christodoulou, I.O.
 2006
 36 S2 p. S85-
1 p.
 article
413 P.220 Host factors are essential for hepatic steatosis in a Lithuanian cohort of patients with chronic hepatitis C infection Speiciene, D.
 2006
 36 S2 p. S129-
1 p.
 article
414 P.413 How much does HIV co-infection impact on HCV viral load: influence of HCV genotypes and HIV infection markers Thibault, V.
 2006
 36 S2 p. S188-
1 p.
 article
415 P.186 Hyper-activation of IRF-1 is associated with co-suppression of HCV replication by interferon combination therapy Zhang, X.
 2006
 36 S2 p. S118-
1 p.
 article
416 P.020 Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site Deng, Q.
 2006
 36 S2 p. S67-
1 p.
 article
417 P.317 Identification of a dominant H-2d restricted Th epitope on capsid protein of hepatitis E virus Wu, T.
 2006
 36 S2 p. S159-
1 p.
 article
418 P.201 Identification of a duplication of the V3 domain in the NS5A region in HCV genotype 1b infected patients: prevalence and relation with clinical outcome in two cohorts Le Guillou-Guillemette, H.
 2006
 36 S2 p. S123-
1 p.
 article
419 P.059 Identification of T-cell responses to the hepatitis B spliced protein (HBSP) of hepatitis B virus Bourgine, M.
 2006
 36 S2 p. S79-
1 p.
 article
420 P.078 Immigration and the epidemiology of chronic hepatitis B in Western Europe Cerri, K.
 2006
 36 S2 p. S85-
1 p.
 article
421 P.341 Immunity to hepatitis B vaccine in asymptomatic HIV-positive South African babies Simani, O.E.
 2006
 36 S2 p. S166-
1 p.
 article
422 P.223 Immunohistochemistry and serum cytokines in chronic hepatitis C patients R-Viso, A.T.
 2006
 36 S2 p. S130-S131
2 p.
 article
423 P.431 Immunological changes in liver parenchyma and peripheral blood cells from patients with fulminant hepatic failure Santos, D.C.M.
 2006
 36 S2 p. S194-
1 p.
 article
424 P.095 Immunological discriminators of HBeAg seroconversion in patients treated with interferon and thymosin Lim, S.G.
 2006
 36 S2 p. S90-
1 p.
 article
425 P.412 Impact of occult HBV infection in HIV patients naive for anti-retroviral therapy Filippini, P.
 2006
 36 S2 p. S188-
1 p.
 article
426 P.351 Impact of routine childhood hepatitis B immunization programs in eliminating hepatitis B virus transmission in the Pacific Bialek, S.R.
 2006
 36 S2 p. S169-
1 p.
 article
427 P.067 Impact of vaccine-induced HBsAg-specific CD4+ T cells on in vitro hepatitis B-virus infection of primary human hepatocytes Röhrl, E.
 2006
 36 S2 p. S81-S82
2 p.
 article
428 P.055 Impact on quality of life of health states induced by chronic hepatitis B infection: estimates from uninfected and infected persons in Spain Herdman, M.J.
 2006
 36 S2 p. S78-
1 p.
 article
429 P.369 Importance of screening colonoscopy among patients with HCV related liver disease Chaparala, H.
 2006
 36 S2 p. S174-
1 p.
 article
430 P.456 Incidence of hepatitis C virus infection in an Egyptian village Bakr, I.
 2006
 36 S2 p. S202-
1 p.
 article
431 P.462 Incidence of needle stick injury among medical students in Bandar Abbas, Iran Dehghani Zahedani, M.
 2006
 36 S2 p. S204-
1 p.
 article
432 P.025 Infection of primary tupaia and human hepatocytes with recombinant human and woolly monkey hepatitis B virus Köck, J.
 2006
 36 S2 p. S69-
1 p.
 article
433 P.066 Infection of woodchuck hepatitis virus in chinese marmots genetically closely related to eastern woodchucks Yang, D.
 2006
 36 S2 p. S81-
1 p.
 article
434 P.328 Infection with hepatitis E virus: first report of a chronic case and molecular characterization of the virus Banas, B.
 2006
 36 S2 p. S162-
1 p.
 article
435 P.275 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients non-responders to alpha interferferon plus ribavirin Cheinquer, H.
 2006
 36 S2 p. S147-
1 p.
 article
436 P.276 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients relapsers to alpha interferferon plus ribavirin Cheinquer, H.
 2006
 36 S2 p. S147-S148
2 p.
 article
437 P.386 Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC Helaly, G.F.
 2006
 36 S2 p. S180-
1 p.
 article
438 P.321 Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-cytopathic and minimally cytopathic viruses Counihan, N.A.
 2006
 36 S2 p. S160-
1 p.
 article
439 P.084 Inhibition of duck hepatitis B virus replication by peptide nucleic acids (PNAs) coupled to a transporter peptide Ndeboko, B.
 2006
 36 S2 p. S87-
1 p.
 article
440 P.171 Inhibition of hepatitis C virus core protein processing promotes viral budding Pène, V.
 2006
 36 S2 p. S113-S114
2 p.
 article
441 P.306 Innate immune response in acute hepatitis E Srivastava, R.
 2006
 36 S2 p. S156-
1 p.
 article
442 P.175 Interaction of serum-derived hepatitis C virus particles (HCVsp) and human hepatocytes: inhibition of binding by anti-E1E2 antibodies Petit, M.
 2006
 36 S2 p. S115-
1 p.
 article
443 P.058 Interferon receptor 1 promoter polymorphisms and susceptibility to chronic hepatitis B virus infection Zhou, J.
 2006
 36 S2 p. S79-
1 p.
 article
444 P.122 Interim analysis: 48 weeks of combination therapy with peginterferon alpha-2b and adefovir followed by 48 weeks of adefovir monotherapy leads to additional biochemical and virological improvement Lutgehetmann, M.
 2006
 36 S2 p. S98-
1 p.
 article
445 P.345 Interruption of perinatal transmission of hepatitis B virus (HBV) with a recombiant yeast derived hepatitis B vaccine - 9 years of follow-up Li, Y.
 2006
 36 S2 p. S167-
1 p.
 article
446 P.305 Intracellular site of replication of hepatitis E virus: a study by confocal laser scanning and FRET microscopy Rehman, S.
 2006
 36 S2 p. S156-
1 p.
 article
447 P.383 Intrahepatic grafts of rat hepatocellular carcinoma h27 with gender dependent hyperexpression of prolactin receptors Ostroukhova, T.Y.
 2006
 36 S2 p. S179-
1 p.
 article
448 P.325 Investigation of hepatitis E virus (HEV) RNA and genotype in sera of Bangladesh Sugitani, M.
 2006
 36 S2 p. S161-
1 p.
 article
449 P.026 In vitro inhibition of HBsAg secretion by single-domain intrabodies Serruys, B.
 2006
 36 S2 p. S69-
1 p.
 article
450 P.423 Is elevated aminotransferase levels a prerequisite to suspect non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease? Amin, M.A.
 2006
 36 S2 p. S191-S192
2 p.
 article
451 P.202 Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? Vallet, S.
 2006
 36 S2 p. S123-S124
2 p.
 article
452 P.312 Isolation and characterization of hepatitis E virus (HEV)-specific T cell clones from an asymptomatic HEV-exposed subject Shata, M.T.
 2006
 36 S2 p. S158-
1 p.
 article
453 P.187 Isolation of human hepatitis C virus and its replication in vitro Salahuddin, S.Z.
 2006
 36 S2 p. S118-
1 p.
 article
454 P.283 Lack of d de novo hepatitis C virus infections and nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients Ross, S.
 2006
 36 S2 p. S149-S150
2 p.
 article
455 P.116 Lamivudine — a therapeutic alternative in acute viral hepatitis B Tatulescu, D.F.
 2006
 36 S2 p. S97-
1 p.
 article
456 P.017 Lamivudine monotherapy can favour the emergence of viral quasispecies with lower susceptibility to other nucleos(t)ide analogues Moriconi, F.
 2006
 36 S2 p. S66-
1 p.
 article
457 P.119 Liver failure due to exacerbation of a lamivudine-resistant, precore mutant HBV infection and adefovir-nonresponse was successfully treated with tenofovir plus lamivudine Katsounas, A.
 2006
 36 S2 p. S97-
1 p.
 article
458 P.361 Liver injury in visceral leishmaniasis (Kala-azar) in children: systematic review Medeiros, F.S.
 2006
 36 S2 p. S172-
1 p.
 article
459 P.511 Liver involvement in inflammatory bowel disease in Qazvin (Iran) Haghazali, S.
 2006
 36 S2 p. S218-
1 p.
 article
460 P.362 Liver stiffness measured by transient elastography: the influence of biochemical activity Coco, B.
 2006
 36 S2 p. S172-
1 p.
 article
461 P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy Hadziyannis, S.J.
 2006
 36 S2 p. S92-
1 p.
 article
462 P.108 Long term antifibrotic action of interferon gamma treatment in patients with chronic hepatitis B virus infection Weng, H.
 2006
 36 S2 p. S94-
1 p.
 article
463 P.255 Long term follow-up of previous hepatitis C virus positive non-responders to interferon monotherapy successfully re-treated with combination therapy: are they really cured? Ciancio, A.
 2006
 36 S2 p. S141-
1 p.
 article
464 P.081 Long-term inhibition of hepatitis B virus in transgenic mice by pseudotyped adeno-associated virus-mediated RNA interference Chen, C.
 2006
 36 S2 p. S86-
1 p.
 article
465 P.251 Long term outcome of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment Chavalitdhamrong, D.
 2006
 36 S2 p. S139-
1 p.
 article
466 P.111 Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B Bhushan, B.
 2006
 36 S2 p. S95-
1 p.
 article
467 P.144 Loss of hepatitis C virus (HCV) infection in HCV antibodies positive patients between 1999 and 2003 assessed by lower antibodies ratio using AxSYM and Vitros automated systems Payan, C.
 2006
 36 S2 p. S105-
1 p.
 article
468 P.002 Low occurrence of occult hepatitis B virus infection (HBV) in patients with liver cirrhosis due to hepatitis C virus (HCV) with or without hepatocellular carcinoma (HCC) Alencar, R.S.S.M.
 2006
 36 S2 p. S61-
1 p.
 article
469 P.454 Low prevalence of antibody to hepatitis C virus in men who have sex with men who do not report a history of injection drug use Buffington, J.
 2006
 36 S2 p. S201-S202
2 p.
 article
470 P.208 Mannose-binding lectin and severity of chronic hepatitis C in Brazilian patients — a study on the relevance of genotypes Pedroso, M.L.A.
 2006
 36 S2 p. S125-S126
2 p.
 article
471 P.407 Meta-analysis of trials evaluating pegylated interferon plus ribavirin in HIV-infected patients Shire, N.J.
 2006
 36 S2 p. S186-
1 p.
 article
472 P.424 Metformin in the treatment of non-alcoholic fatty liver disease De Lusong, M.A.
 2006
 36 S2 p. S192-
1 p.
 article
473 P.288 Microsomal triglyceride transfer protein gene promoter polymorphism (493g allele) is associated with severity of hcv-associated steatosis Price, D.A.
 2006
 36 S2 p. S151-
1 p.
 article
474 P.061 Modeling clinical benefits of suppressing viral replication in HBeAg-negative chronic hepatitis B (CHB) patients: a number-needed-to-treat (NNT) analysis of entecavir and adefovir Iloeje, U.
 2006
 36 S2 p. S80-
1 p.
 article
475 P.467 Modes of transmission of the hepatitis C virus in France between 1995 and 2001: an incident case-control study Delarocque-Astagneau, E.
 2006
 36 S2 p. S205-S206
2 p.
 article
476 P.233 Modified combination therapy with interferon and ribavirin in the treatment of elderly patients infected with genotype 1b and high viral loads Kohno, H.
 2006
 36 S2 p. S134-
1 p.
 article
477 P.210 Modulation of RANTES expression by HCV core protein in liver derived cell lines Ruggieri, A.
 2006
 36 S2 p. S126-
1 p.
 article
478 P.216 Molecular analysis of genetic variability and epitope stability in a type 1b recurrent HCV infection Sagnelli, E.
 2006
 36 S2 p. S128-
1 p.
 article
479 P.040 Molecular characterization of HBV genotypes newly diagnosed in 2004 in southern France Tamalet, C.
 2006
 36 S2 p. S73-
1 p.
 article
480 P.126 Molecular characterization of HBV genotypes newly diagnosed in 2004 in southern France Tamalet, C.
 2006
 36 S2 p. S99-
1 p.
 article
481 P.333 Molecular epidemiology of hepatitis A virus in western India (1981–2005) Arankalle, V.A.
 2006
 36 S2 p. S163-
1 p.
 article
482 P.310 Molecular investigations and epidemiological tracing of hepatitis A virus strains in a low incident area over 16 years Makhaeva-Azemovic, L.
 2006
 36 S2 p. S157-
1 p.
 article
483 P.100 Molecular profile of hepatitis B virus (HBV) based in the pre-S/S gene variability Silva Filho, H.P.
 2006
 36 S2 p. S91-S92
2 p.
 article
484 P.460 Molecular typing of hepatitis C cases in one Swedish county during one year Jern, C.
 2006
 36 S2 p. S203-S204
2 p.
 article
485 P.507 Monitoring of active infection by CMV, HHV-6 and HHV-7 in hepatic transplant receivers by antigenemia and N-PCR Sampaio, A.
 2006
 36 S2 p. S217-
1 p.
 article
486 P.381 Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis Quarta, S.
 2006
 36 S2 p. S178-
1 p.
 article
487 P.289 Morphologic study of chronic hepatitis C in oriental Amazon region (Brazil) focusing on stellate hepatic cells and extracellular matrix using confocal microscopy Demachki, S.
 2006
 36 S2 p. S152-
1 p.
 article
488 P.391 Multidisciplinary approach in liver cancer: how applicable in Greece? Christodoulou, I.O.
 2006
 36 S2 p. S181-
1 p.
 article
489 P.069 Mutations in core immune epitopes in different promoter and precore mutants in chronic e antigen negative hepatitis B Sendi, H.
 2006
 36 S2 p. S82-
1 p.
 article
490 P.211 Natural history of chronic HCV infection: potential influence of polymorphisms in cytokine and HFE gene Abdullaev, S.M.
 2006
 36 S2 p. S126-S127
2 p.
 article
491 P.227 Natural history of hepatitis C in twenty patients detected at the early stage of infection Gaudy, C.
 2006
 36 S2 p. S132-
1 p.
 article
492 P.074 Neopterin levels in patients who are in different phases of hepatitis B virus infection Demirturk, N.
 2006
 36 S2 p. S83-S84
2 p.
 article
493 P.284 Neurocognitive alterations in patients with HCV infection with and without abnormal transaminases D'Aloiso, C.M.
 2006
 36 S2 p. S150-
1 p.
 article
494 P.438 Newly referred hepatitis C patients: changes in epidemiological profile over time Pradat, P.
 2006
 36 S2 p. S196-
1 p.
 article
495 P.028 No amplification of the hepatitis B virus covalently closed circular DNA after in vitro infection of the human hepatoma HepaRG cells Hantz, O.
 2006
 36 S2 p. S69-S70
2 p.
 article
496 P.103 No evidence for ADV resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years Lampertico, P.
 2006
 36 S2 p. S92-S93
2 p.
 article
497 P.425 Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? De Lusong, M.A.
 2006
 36 S2 p. S192-
1 p.
 article
498 P.364 Noninvasive prediction of cirrhosis in patients with chronic hepatitis C: prospective comparison of Lok index, Fibroscan, Fibrotest and APRI with liver biopsy Castera, L.
 2006
 36 S2 p. S173-
1 p.
 article
499 P.478 Nosocomial transmission of hepatitis C virus infection in hemodialysis patients in Brazil: phylogenetic evidence Lampe, E.
 2006
 36 S2 p. S209-
1 p.
 article
500 P.158 Novel interferon alpha variant with improved inhibitory activity against HCV genotype 1 replication compared to IFN alpha-2b therapy, in a subgenomic replicon system Escuret, V.
 2006
 36 S2 p. S109-
1 p.
 article
501 P.377 Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians Mendy, M.E.
 2006
 36 S2 p. S177-
1 p.
 article
502 P.340 Observed and model-based persistence of antibodies after hepatitis A vaccination: a review Van Herck, K.
 2006
 36 S2 p. S165-
1 p.
 article
503 P.136 Occult B infection in the Brazilian northeastern region: a preliminary report Almeida, D.
 2006
 36 S2 p. S102-
1 p.
 article
504 P.402 Occult hepatitis B virus infection in French patients with chronic hepatitis C Mrani, S.
 2006
 36 S2 p. S184-S185
2 p.
 article
505 P.196 Occult persistence of hepatitis C virus Pham, T.N.Q.
 2006
 36 S2 p. S121-
1 p.
 article
506 P.479 Occupational exposures to HBV and HCV among healthcare workers in Canada McCarthy, G.M.
 2006
 36 S2 p. S209-S210
2 p.
 article
507 P.018 Opposing effects of two naturally occurring mutations in hepatitis B virus core protein on 2nd strand DNA synthesis Kim, K.
 2006
 36 S2 p. S66-S67
2 p.
 article
508 P.482 Oral fluids as a medium for prevalence studies on viral hepatitis A, b and C Vranckx, R.
 2006
 36 S2 p. S210-
1 p.
 article
509 P.044 Organ specific gene expression profile reflect distinguished pathogenesis in liver and kidney during HBV persistence — a study in HBV transgenic mouse model Ren, J.
 2006
 36 S2 p. S74-
1 p.
 article
510 P.231 Outcome of decompensated hepatitis C virus-related cirrhotic patients treated with peg-interferon alpha-2b and ribavirin. A controlled study Iacobellis, A.
 2006
 36 S2 p. S133-
1 p.
 article
511 P.378 Overexpression of Nek2 in hepatocellular carcinoma Chen, Y.
 2006
 36 S2 p. S177-
1 p.
 article
512 P.419 Patients infected with HIV/HCV and the liver injury as a side effect of HAART Dragovic, G.J.
 2006
 36 S2 p. S190-
1 p.
 article
513 P.260 Peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive Egyptian patients El-Wakil, R.M.
 2006
 36 S2 p. S142-S143
2 p.
 article
514 P.244 Pegylated interferon alpha-2a for treatment of acute hepatitis C in Egypt (ANRS 1213 trial) Ismail, S.A.
 2006
 36 S2 p. S137-
1 p.
 article
515 P.324 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta Niro, G.A.
 2006
 36 S2 p. S161-
1 p.
 article
516 P.320 Persistence and dissemination of hepatitis A virus genotype 3 in France Mackiewicz, V.
 2006
 36 S2 p. S160-
1 p.
 article
517 P.384 Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug® (DT) for patients with advanced hepatocellular carcinoma (HCC) Merle, P.
 2006
 36 S2 p. S179-
1 p.
 article
518 P.092 Phenoscript-HBV®: a high throughput phenotyping test to evaluate the drug susceptibility of HBV strains isolated from patients Barraud, L.
 2006
 36 S2 p. S89-S90
2 p.
 article
519 P.287 Phylogenetic analysis of hepatitis C infection in South Australia Chang, G.L.
 2006
 36 S2 p. S151-
1 p.
 article
520 P.219 Phylogeny of HCV in a rural village of Egypt: intrafamilial comparison of sequences El-Daly, M.
 2006
 36 S2 p. S129-
1 p.
 article
521 P.396 Plasma ribavirin concentrations during treatment of recurrent hepatitis C after liver transplantation Dumortier, J.
 2006
 36 S2 p. S182-S183
2 p.
 article
522 P.207 Polymorphisms in the interleukin 10 promoter gene in chronic hepatitis C patients treated with interferon and ribavirin Melo, C.E.
 2006
 36 S2 p. S125-
1 p.
 article
523 P.300 Porphyria cutanea tarda and hepatitis C infection: a case report Tengan, F.M.
 2006
 36 S2 p. S155-
1 p.
 article
524 P.065 Precore and core promoter mutations or serum HBV DNA levels do not allow to distinguish true inactive HBsAg carriers from HBeAg negative chronic hepatitis B with fluctuating ALT Martinot-Peignoux, M.M.
 2006
 36 S2 p. S81-
1 p.
 article
525 P.041 Precore, core promoter and X gene mutations of hepatitis B virus in Thai patients with hepatocellular carcinoma: a case-control study Tangkijvanich, P.
 2006
 36 S2 p. S73-
1 p.
 article
526 P.052 Predicting liver disease complications (HCC and cirrhosis) in patient with chronic hepatitis B infection using a risk function model: the R.E.V.E.A.L.-HBV study Chen, C.J.
 2006
 36 S2 p. S77-
1 p.
 article
527 P.247 Prediction of treatment outcome in genotype 4 chronic hepatitis C patients during combined pegylated interferon alpha-2a and ribavirin therapy (ANRS 1211 trial) Esmat, G.
 2006
 36 S2 p. S138-
1 p.
 article
528 P.129 Predictors of HBV immunization in Canadian healthcare workers McCarthy, G.M.
 2006
 36 S2 p. S100-S101
2 p.
 article
529 P.329 Presence of hepatitis E virus (HEV) in pigs enhances their possible role as reservoir for animal-to-human transmission in France Pavio, N.
 2006
 36 S2 p. S162-S163
2 p.
 article
530 P.326 Presence of hepatitis E virus in sewage in northern India: frequency and seasonal pattern Kumar, S.I.
 2006
 36 S2 p. S162-
1 p.
 article
531 P.461 Prevalence and risk factors of hepatitis C among pregnant females in Egypt Metwally, M.A.
 2006
 36 S2 p. S204-
1 p.
 article
532 P.465 Prevalence of anti-HEV in veterans who have been at war or have not been at war in Afghanistan in 1979–1989 Michailov, M.I.
 2006
 36 S2 p. S205-
1 p.
 article
533 P.477 Prevalence of diabetes among adults with viral hepatitis in Puerto Rico Pérez, C.M.
 2006
 36 S2 p. S209-
1 p.
 article
534 P.498 Prevalence of hepatitis B and C in Constantine in 2005 Semra, Z.
 2006
 36 S2 p. S214-
1 p.
 article
535 P.449 Prevalence of hepatitis B and C in Evenk ethnicity in Saha Republic (Yakutia) Popova, O.E.
 2006
 36 S2 p. S200-
1 p.
 article
536 P.440 Prevalence of hepatitis B and hepatitis C in France, 2004 Meffre, C.
 2006
 36 S2 p. S197-
1 p.
 article
537 P.470 Prevalence of hepatitis B antibodies in health-care workers in Yasuj/Iran hospitals Sarkari, B.
 2006
 36 S2 p. S206-S207
2 p.
 article
538 P.128 Prevalence of hepatitis B virus genotypes and surface antigen variants in French blood donors Servant-Delmas, A.
 2006
 36 S2 p. S100-
1 p.
 article
539 P.474 Prevalence of hepatitis C, B and D markers among population of prisoners in Croatia Burek, V.
 2006
 36 S2 p. S208-
1 p.
 article
540 P.418 Prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) infection among HIV infected persons (France, 2004) Larsen, C.
 2006
 36 S2 p. S190-
1 p.
 article
541 P.485 Prevalence of isolated anti-HBC in previously HBV infected individuals Hasanjani Roushan, M.R.
 2006
 36 S2 p. S211-
1 p.
 article
542 P.133 Prevalence of markers of hepatotropic virus B and the efficacy of vaccination against hepatitis B among medical students in Bandar Abbas, Iran Mahouri, K.
 2006
 36 S2 p. S101-
1 p.
 article
543 P.509 Prevalence of virus serological markers of hepatitis B and C in voluntary donations in blood bank of University Hospital Alzira Velano Magalhães, M.B.C.
 2006
 36 S2 p. S217-S218
2 p.
 article
544 P.010 Prevalency of hepatitis B with normal and elevated serum alanine aminotransferase in a part of population in Azerbaijan Republic Najafizadeh, M.
 2006
 36 S2 p. S64-
1 p.
 article
545 P.099 Primary resistance of a novel hepatitis B virus variant to adefovir Schildgen, O.
 2006
 36 S2 p. S91-
1 p.
 article
546 P.181 Production of enveloped E1E2 hepatitis C virus particles in primary cultured hepatocytes from chronically infected patients Petit, M.
 2006
 36 S2 p. S116-S117
2 p.
 article
547 P.436 Propagation of HBV in a rat hepatoma cell line stably transfected with human annexin V Carman, W.
 2006
 36 S2 p. S196-
1 p.
 article
548 P.387 Prospective analysis of risk factors for hepatocellular carcinoma in cirrhotic patients with a risk calculator system Tsai, J.
 2006
 36 S2 p. S180-
1 p.
 article
549 P.350 Randomised controlled trial: 2- vs 3-dose hepatitis B immunization of adolescents Heron, L.
 2006
 36 S2 p. S168-S169
2 p.
 article
550 P.409 Rapid course of liver fibrosis progression in patients dually infected by HIV and HCV despite high CD4 and HAART (evaluation with two successive liver biopsies) Bonnard, P.
 2006
 36 S2 p. S187-
1 p.
 article
551 P.253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients Persico, M.
 2006
 36 S2 p. S140-
1 p.
 article
552 P.335 Rare heavy cholestatic form of acute hepatitis a treated with UDCA Boykinova, O.B.
 2006
 36 S2 p. S164-
1 p.
 article
553 P.337 Rational design of HCV vaccine cocktails that maximize coverage of potential CTL epitopes Yusim, K.
 2006
 36 S2 p. S164-S165
2 p.
 article
554 P.221 ‘Reactivation’ of hepatitis C in a child who was infected perinatally Boxall, E.H.
 2006
 36 S2 p. S130-
1 p.
 article
555 P.463 Recent data on acute hepatitis B infections in France through mandatory notification Antona, D.G.
 2006
 36 S2 p. S204-
1 p.
 article
556 P.249 Recurrence or persistence of HCV RNA detectable only by TMA during antiviral therapy Gelderblom, H.C.
 2006
 36 S2 p. S139-
1 p.
 article
557 P.397 Rejection under interferon alpha therapy in liver transplant patients Walter, T.
 2006
 36 S2 p. S183-
1 p.
 article
558 P.167 Relative contribution of core and alternate reading frame protein of HCV to chemokine release by monocytic cells: Implications for HCV pathogenesis Fiorucci, M.
 2006
 36 S2 p. S112-
1 p.
 article
559 P.459 Replacement of hepatitis C virus genotype 1b by genotype 2 over a 10 year period in Venezuela Pujol, F.H.
 2006
 36 S2 p. S203-
1 p.
 article
560 P.174 Replication activities of chimeric subgenomic GB virus B replicons containing 5′ nontranslated RNA sequences of hepatitis C virus Warter, L.
 2006
 36 S2 p. S114-S115
2 p.
 article
561 P.176 Replication of the HCV replicon in human myeloleukemia L-41 cells Oniangue, C.
 2006
 36 S2 p. S115-
1 p.
 article
562 P.188 Replicative intermediate RNA detection during yellow fever virus infections in chicken embryos Oliveira, B.E.P.D.
 2006
 36 S2 p. S118-S119
2 p.
 article
563 P.453 Representation of HCV care among prisoners agauP. Chossegros 2006
 36 S2 p. S201-
1 p.
 article
564 P.177 Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes Ciccaglione, A.
 2006
 36 S2 p. S115-
1 p.
 article
565 P.155 Research of immune response dynamics in patients with acute and chronic viral hepatitis C depending on form of the disease Gramatyuk, S.N.
 2006
 36 S2 p. S108-
1 p.
 article
566 P.046 Resolution of acute hepatitis B virus infections Reaiche, G.Y.
 2006
 36 S2 p. S75-
1 p.
 article
567 P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] Marcellin, P.
 2006
 36 S2 p. S95-S96
2 p.
 article
568 P.259 Retreatment with peginterferon alpha-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients in whom pegylated interferon alpha-2b (12KD)/ribavirin has failed: planned week-12 efficacy and safety analysis of the repeat study Marcellin, P.
 2006
 36 S2 p. S142-
1 p.
 article
569 P.157 Revisiting HCV E2 amino acid sequence variability: Tentative definition of a novel hypervariable region Troesch, M.
 2006
 36 S2 p. S109-
1 p.
 article
570 P.457 Risk behaviors and hepatitis C virus (HCV) infection among new- and long-term injection drug users (IDUs) Oliveira, M.L.A.
 2006
 36 S2 p. S202-S203
2 p.
 article
571 P.070 Risk behaviour and motivation of hepatitis B cases in blood donors during 2005 Kasraian, L.
 2006
 36 S2 p. S82-S83
2 p.
 article
572 P.497 Risk behaviour and motivation of hepatitis C cases in blood donors during 2005 Kasraian, L.
 2006
 36 S2 p. S214-
1 p.
 article
573 P.426 Risk factors and liver test abnormality in patients with NAFLD Sadr, F.
 2006
 36 S2 p. S192-
1 p.
 article
574 P.447 Risk factors for HCV seropositivity — case-control study on blood donors: immigrants from the former Soviet Union as compared to other blood donors Kerzman, H.
 2006
 36 S2 p. S199-
1 p.
 article
575 P.446 Risk factors of acute hepatitis C virus (HCV) infection: results of a nationwide surveillance system in Italy Mariano, A.
 2006
 36 S2 p. S199-
1 p.
 article
576 P.168 Role of chaperonin-containing TCP complex (CCT) and heat shock cognate protein 70 (Hsc70) in the HCV RNA replication Suzuki, T.
 2006
 36 S2 p. S112-S113
2 p.
 article
577 P.408 Safety and efficacy of a 24-week course of pegylated interferon α-2a and ribavirin for the treatment of acute HCV infection in HIV positive patients Dominguez, S.S.D.
 2006
 36 S2 p. S186-S187
2 p.
 article
578 P.296 Safety issues of hemotransfusion concerning hepatitis C in Republic of Tatarstan Yuzlibaeva, L.R.
 2006
 36 S2 p. S153-S154
2 p.
 article
579 P.428 SCCA over-expression induces cell proliferation and down-regulation of the adhesion system Quarta, S.
 2006
 36 S2 p. S193-
1 p.
 article
580 P.147 Screening for HCV in risk groups by Austrian general practitioners increases the detection rate of hepatitis C Munda, P.E.
 2006
 36 S2 p. S106-
1 p.
 article
581 P.307 Search for sporadic acute viral hepatitis cases with type-4 hepatitis E virus in western India Arankalle, V.A.
 2006
 36 S2 p. S156-
1 p.
 article
582 P.145 Selection and persistence of occult minority genotype 2b hepatitis C infection in a patient treated with 48 weeks of pegylated interferon alpha-2b and ribavirin for genotype 5a Buckton, A.J.
 2006
 36 S2 p. S105-
1 p.
 article
583 P.091 Selection and phenotypic characterization of multiple drug resistant variants in patients with chronic hepatitis B Villet, S.
 2006
 36 S2 p. S89-
1 p.
 article
584 P.088 Sensitivity of hepatitis B surface antigen assays to detect HBsAg mutant forms Laperche, S.
 2006
 36 S2 p. S88-
1 p.
 article
585 P.375 Sequence variation in the enhancer 2/basal core promoter/precore region of hepatitis B virus and subsequent risk for hepatocellular carcinoma Yu, M.
 2006
 36 S2 p. S176-
1 p.
 article
586 P.114 Sequential lamivudine and adefovir therapy maintains seroconversion rates in patients with HBeAg+ chronic hepatitis B Lim, S.G.
 2006
 36 S2 p. S96-
1 p.
 article
587 P.134 Seroepidemiology of HBV and efficacy of hepatitis B vaccine in nursing and obstetrics students, Bonab City, Iran, 2004 Montazam, S.H.
 2006
 36 S2 p. S102-
1 p.
 article
588 P.323 Serological and molecular evidence of hepatitis E virus infection in swine and environmental samples from a commercial herd in Rio de Janeiro, Brazil Santos, D.R.L.
 2006
 36 S2 p. S160-S161
2 p.
 article
589 P.206 Serological, clinical, and demographic correlates of the outcome of hepatitis C virus infection Wietzke-Braun, P.
 2006
 36 S2 p. S125-
1 p.
 article
590 P.441 Serological, epidemiological and molecular aspects of hepatitis B virus infection in the largest Afro-Brazilian isolated community Martins, R.
 2006
 36 S2 p. S197-
1 p.
 article
591 P.156 Serologic profiles at the haemodialysis in Hospital constantine (Algeria) Ait Kaki, B.
 2006
 36 S2 p. S109-
1 p.
 article
592 P.448 Seroprevalence and age of acquirement of HBV infection during childhood in “Complexe pediartique de Bangui” (Central African Republic) Komas, N.P.
 2006
 36 S2 p. S199-S200
2 p.
 article
593 P.483 Seroprevalence of HBV, HCV and HIV among intravenous drug users in Iran Karimi, A.
 2006
 36 S2 p. S210-S211
2 p.
 article
594 P.421 Serum adiponectin levels are associated with the severity of liver steatosis in chronic hepatitis B or C Tsochatzis, E.
 2006
 36 S2 p. S191-
1 p.
 article
595 P.230 Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C (ANRS 1211) Males, S.
 2006
 36 S2 p. S133-
1 p.
 article
596 P.367 Serum levels of astroglial S100β and neuron-specific enolase (NSE) in patients with liver cirrhosis with and without hepatic encephalopathy Radwan, A.S.
 2006
 36 S2 p. S174-
1 p.
 article
597 P.295 Serum markers of early response to treatment of hepatitis C Cunha, S.F.
 2006
 36 S2 p. S153-
1 p.
 article
598 P.121 Severe acute exacerbation of HBeAg-negative chronic hepatitis B has good maintained response to lamivudine treatment Chan, H.
 2006
 36 S2 p. S97-S98
2 p.
 article
599 P.125 Severe reactivation of hepatitis B virus: experience of a single centre Antonini, T.M.
 2006
 36 S2 p. S99-
1 p.
 article
600 P.252 Short term treatment with peginterferon and ribavirin for HCV genotype 2 or 3 patients Gill, M.L.
 2006
 36 S2 p. S139-S140
2 p.
 article
601 P.085 Short treatment schedule may be effective in rapid viral responders to peg-interferon plus ribavirin for genotype 1 chronic hepatitis C Bonardi, R.
 2006
 36 S2 p. S87-
1 p.
 article
602 P.493 Significant reduction of hepatitis B virus prevalence in blood donors referred to Ahwaz blood transfusion service in 2005 (Iran) Torabi Zadeh Maatoghi, J.
 2006
 36 S2 p. S213-
1 p.
 article
603 P.366 Simple blood tests as non-invasive markers of liver fibrosis in hemodialysis patients with hepatitis C virus (HCV) chronic infection Schiavon, L.L.
 2006
 36 S2 p. S173-
1 p.
 article
604 P.505 Smoking habits and liver histological lesions in chronic viral hepatitis Tsochatzis, E.
 2006
 36 S2 p. S216-
1 p.
 article
605 P.053 Spliced hepatitis B virus RNA and liver disease Soussn, P.
 2006
 36 S2 p. S77-
1 p.
 article
606 P.064 Spontaneous clearance of HBV markers among HBV carriers from an area of northeastern Brazil where genotype A prevails Almeida, D.
 2006
 36 S2 p. S81-
1 p.
 article
607 P.225 Spontaneous viral clearance in patients with acute hepatitis C in Egypt Sharaf El-Din, N.M.
 2006
 36 S2 p. S131-
1 p.
 article
608 P.194 Spread of the natural hepatitis C virus recombinant outside Russia Kalinina, O.
 2006
 36 S2 p. S120-S121
2 p.
 article
609 P.214 Steatosis in chronic HCV infection: viral and host characteristics Price, D.A.
 2006
 36 S2 p. S127-S128
2 p.
 article
610 P.269 Steatosis, overweight and response to antiviral treatment in chronic hepatitis C Szanto, P.G.
 2006
 36 S2 p. S145-
1 p.
 article
611 P.042 Studies on the control of HBV infection in a mouse model of acute hepatitis B Svorcova, M.
 2006
 36 S2 p. S73-
1 p.
 article
612 P.012 Study of cccDNA formation and resistance to nucleoside analogs using an improved hepatitis B virus recombinant baculovirus-HepG2 system Lucifora, J.
 2006
 36 S2 p. S64-S65
2 p.
 article
613 P.016 Successful transfection of macaca Cynomolgus with cloned human hepatitis B virus Chemin, I.A.
 2006
 36 S2 p. S66-
1 p.
 article
614 P.357 Superimposed activation of the immune system by superantigen associated with hepatic inflammation in SIVmac-infected rhesus monkeys Chen, Z.W.
 2006
 36 S2 p. S171-
1 p.
 article
615 P.471 Surveillance for chronic hepatitis C virus infection in the USA: 2003–2005 Gallagher, K.M.
 2006
 36 S2 p. S207-
1 p.
 article
616 P.443 Sustained transmission of hepatitis B in the Netherlands, despite vaccination targeted towards high-risk groups Van Houdt, R.
 2006
 36 S2 p. S198-
1 p.
 article
617 P.169 Targeting of hepatitis C virus-heparan sulfate by human anti-viral antibodies Barth, H.
 2006
 36 S2 p. S113-
1 p.
 article
618 P.182 Temporal patterns of hepatitis C virus quasispecies in chronically infected patients Ramachandran, S.
 2006
 36 S2 p. S117-
1 p.
 article
619 P.039 The APOBEC3C protein induces massive guanosine to adenosine hypermutations in hepatitis B virus genomes Köck, J.
 2006
 36 S2 p. S72-
1 p.
 article
620 P.510 The assessment of cholestatic hepatitis in viral and drugs induced hepatic lesions Tanasescu, V.I.
 2006
 36 S2 p. S218-
1 p.
 article
621 P.130 The changes of serum aminotransferase after strenuous exercise in hepatitis B virus carriers Hsueh, C.W.
 2006
 36 S2 p. S101-
1 p.
 article
622 P.097 The competing roles of virus replication rates and hepatocyte death rates in the emergence of drug resistant hepatitis B virus mutants: theoretical considerations Litwin, S.
 2006
 36 S2 p. S91-
1 p.
 article
623 P.495 The correlation between HCV and dental staff Kuzekanani, M.
 2006
 36 S2 p. S214-
1 p.
 article
624 P.076 The cost of hepatitis B in Germany Dale, P.
 2006
 36 S2 p. S84-
1 p.
 article
625 P.435 The cytokines variations and lymphocytic sets in patients with viral hepatitis and rheumatoid arthritis Bezna, S.
 2006
 36 S2 p. S195-
1 p.
 article
626 P.033 The cytosolic precore protein of the hepatitis B virus: a retrotransport from endoplasmic reticulum to cytosol? Duriez, M.
 2006
 36 S2 p. S71-
1 p.
 article
627 P.031 The determinant of hepatitis B surface antigen (HBsAg) serotype at the amino acid residue 122 is crucial for the antigenicity of HBsAg Tian, Y.
 2006
 36 S2 p. S70-
1 p.
 article
628 P.021 The effects of APOBEC3G on HBV replication Mohammed, E.
 2006
 36 S2 p. S67-
1 p.
 article
629 P.246 The efficacy of a 12 weeks course of pegylated interferon alpha-2b (Peg-IFN) and ribavirin (RBV) is similar to a standard 24 weeks course, regardless of basal viremic level Bonardi, R.
 2006
 36 S2 p. S138-
1 p.
 article
630 P.005 The evaluation of IgG avidity tests in the diagnosis of acute hepatitis A and B infections Paver, K.
 2006
 36 S2 p. S62-
1 p.
 article
631 P.500 “The first shot”: the context of first injection of illicit drugs, ongoing injecting practices and hepatitis C virus (HCV) infection Oliveira, M.L.A.
 2006
 36 S2 p. S215-
1 p.
 article
632 P.045 The hepatitis B virus x protein up-regulates gamma aminobutyric acid type A β3 receptor expression Sidorkiewicz, M.
 2006
 36 S2 p. S74-S75
2 p.
 article
633 P.427 The hepatitis E virus ORF3 protein modulates endocytic trafficking and the acute phase protein response Kar-Roy, A.
 2006
 36 S2 p. S193-
1 p.
 article
634 P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT) Rockstroh, J.
 2006
 36 S2 p. S187-S188
2 p.
 article
635 P.445 The knowledge and behaviors of HCV-infected persons identified in a seroprevalence survey, USA, 2001–2002 Wasley, A.
 2006
 36 S2 p. S198-S199
2 p.
 article
636 P.006 The new HBsAg Elisa-kit “DS-EIA-HBsAg-0.01” with the increased sensitivity Ulanova, T.I.
 2006
 36 S2 p. S62-S63
2 p.
 article
637 P.464 The pathosystems resource integration center: implication for viral pathogens Shallom, J.M.
 2006
 36 S2 p. S205-
1 p.
 article
638 P.280 Therapeutic effect of interferon alpha-2b in a case of acute hepatitis C and splenic marginal zone B-cell lymphoma Boykinova, O.B.
 2006
 36 S2 p. S149-
1 p.
 article
639 P.267 Therapy with natural leukocyte interferon and ribavirin in “difficult to treat” patients infected with HCV Janczewska-Kazek, E.
 2006
 36 S2 p. S144-S145
2 p.
 article
640 P.360 The relationship between insulin resistance and fibrosis progression in chronic hepatitis C Fernando, C.J.
 2006
 36 S2 p. S171-S172
2 p.
 article
641 P.343 The relative efficacy of hepatitis A vaccine versus immune globulin for postexposure prophylaxis Victor, J.C.
 2006
 36 S2 p. S166-S167
2 p.
 article
642 P.404 The response of a patient with dual hepatitis B and hepatitis C virus coinfection to pegylated interferon plus ribavirin therapy: a case report Akhan, S.
 2006
 36 S2 p. S185-
1 p.
 article
643 P.322 The role of interferon alpha for limited growth of hepatitis A virus in cell culture Counihan, N.A.
 2006
 36 S2 p. S160-
1 p.
 article
644 P.098 The role of therapeutic vaccination in replicative carriers of hepatitis virus (HBV) and its effect on cytokine profile Singhal, S.
 2006
 36 S2 p. S91-
1 p.
 article
645 P.071 The serial diversity of surface gene on hepatitis B viral population in a child with failed perinatal prophylaxis Kim, J.
 2006
 36 S2 p. S83-
1 p.
 article
646 P.049 The terminal protein of hepatitis B virus interferes with the regulation of cellular interferon stimulated genes and reduces the ability of cells to establish antiviral status Xu, Y.
 2006
 36 S2 p. S76-
1 p.
 article
647 P.106 The use of lamivudine for preddicted fulminant hepatic failure in severe acute viral hepatitis type b — a two-year study Radulescu, A.L.
 2006
 36 S2 p. S93-S94
2 p.
 article
648 P.297 Three cases of acute hepatitis C virus infection following dry sex Lewis-Ximenez, L.L.
 2006
 36 S2 p. S154-
1 p.
 article
649 P.376 TP53 mutation at codon 249 in circulating DNA of healthy patients exposed to aflatoxin: relation with HBV infection and significance for assessment of carcinogen exposure Le Roux, E.
 2006
 36 S2 p. S176-S177
2 p.
 article
650 P.014 Tracing early events of hepatitis B virus infection Schulze, A.
 2006
 36 S2 p. S65-
1 p.
 article
651 P.318 Transfusion transmitted hepatitis E in a ‘non hyperendemic’ country Boxall, E.H.
 2006
 36 S2 p. S159-
1 p.
 article
652 P.248 Treatment of chronic hepatitis C (CHC) with pegylated interferon plus ribavirin in real life. One center experience Bonny, C.B.
 2006
 36 S2 p. S138-S139
2 p.
 article
653 P.258 Treatment of nonresponders/relapsers to interferon with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in routine clinical practice: factors predicting SVR using multiple logistic regression analysis Sherman, M.
 2006
 36 S2 p. S142-
1 p.
 article
654 P.268 Treatment of patients infected with hepatitis C virus genotype 4 in Portugal — retrospective study Gloria, H.
 2006
 36 S2 p. S145-
1 p.
 article
655 P.398 Treatment of recurrent post-liver transplantation hepatitis C: a single cohort analysis Chermak, F.
 2006
 36 S2 p. S183-
1 p.
 article
656 P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin Zeuzem, S.
 2006
 36 S2 p. S136-
1 p.
 article
657 P.437 Trends in hepatitis A mortality in the USA, 1983–2002 Vogt, T.M.
 2006
 36 S2 p. S196-
1 p.
 article
658 P.490 Trends in incidence of hepatitis B and C in Fars blood donors from 2002 till end 2006 Kasrraian, L.
 2006
 36 S2 p. S212-
1 p.
 article
659 P.382 Trends in mortality from liver cancer in the USA, 1993–2002 Perz, J.F.
 2006
 36 S2 p. S178-
1 p.
 article
660 P.476 Tweedledum and tweedledee: how well are we controlling hepatitis B and C? Vickery, K.
 2006
 36 S2 p. S208-S209
2 p.
 article
661 P.234 Ultrastructural and apoptotic changes of mononuclear cells in patients with HCV infection Ghanem, L.Y.
 2006
 36 S2 p. S134-
1 p.
 article
662 P.131 Ultrastructural study of peripheral blood mononuclear cells in chronic type B hepatitis Ghanem, L.Y.
 2006
 36 S2 p. S101-
1 p.
 article
663 P.101 Unusual selection of rta181V HBV mutants cross-resistant to adefovir under lamivudine monotherapy: report of two cases Gerolami, R.
 2006
 36 S2 p. S92-
1 p.
 article
664 P.417 Usefulness of the AST to platelet ratio index (APRI) for predicting liver fibrosis in HIV/HCV co-infected patients Carvalho Filho, R.J.
 2006
 36 S2 p. S189-S190
2 p.
 article
665 P.363 Validation of hepascore for diagnosis of liver fibrosis in HCV patients and determination of a new algorithm Bourlière, M.
 2006
 36 S2 p. S172-
1 p.
 article
666 P.370 Validation of the Korean version of liver disease quality of life (LDQOL 1.0) instrument Hwang, S.
 2006
 36 S2 p. S174-S175
2 p.
 article
667 P.107 Variant strains of HBV contribute to clinical outcome of combination therapy with lamivudine and interferon-alpha in tolerant children with chronic hepatitis B Carey, I.
 2006
 36 S2 p. S94-
1 p.
 article
668 P.013 Vectorial export of hepatitis B virus Bhat, P.
 2006
 36 S2 p. S65-
1 p.
 article
669 P.502 Very low prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study Reis, F.
 2006
 36 S2 p. S215-
1 p.
 article
670 P.165 Viral fitness within the hepatitis C virus protease Soderholm, J.
 2006
 36 S2 p. S112-
1 p.
 article
671 P.195 Virological and clinical aspect of occult HBV infection in patient with chronic hepatitis C: a multicentre study Sagnelli, E.
 2006
 36 S2 p. S121-
1 p.
 article
672 P.056 Virological and clinical correlates of hepatitis B virus (HBV) DNA levels in patients with HBe-negative, genotype D chronic hepatitis B Chevaliez, S.
 2006
 36 S2 p. S78-
1 p.
 article
673 P.096 Virological markers and immune response in woodchucks WHV chronic carriers, following lamivudine pre-S/S vaccine therapy D'Ugo, E.
 2006
 36 S2 p. S90-
1 p.
 article
674 P.264 Viusid in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Efficacy and safety results from a ramdomized controlled trial Vilar Gómez, E.
 2006
 36 S2 p. S144-
1 p.
 article
675 P.406 Weak and delayed hepatitis C virus-specific T cell responses during acute hepatitis C in HIV-infected patients Schnuriger, A.
 2006
 36 S2 p. S186-
1 p.
 article
676 P.342 20 year follow-up of hepatitis B vaccination in the institutionalized mentally retarded Van Damme, P.
 2006
 36 S2 p. S166-
1 p.
 article
                             676 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands